Note: Descriptions are shown in the official language in which they were submitted.
CA 02897444 2015-07-07
WO 2014/110053
PCT/US2014/010553
USE OF iNOS INHIBITORS TO INCREASE VIRAL YIELD IN CULTURE
TECHNICAL FIELD
The present invention relates generally to methods for producing viruses and
recombinant virions in culture. In particular, the invention pertains to the
use of the
iNOS inhibitors, such as aurintricarboxylic acid, dexamethasone and valproic
acid to
increase the yield of a variety of viruses in culture, including recombinant
herpesviruses which can in turn be used as helpers for the production of
recombinant
adeno-associated virus virions.
BACKGROUND
Herpesviruses are highly disseminated in nature and found in most animal
species. At least 100 herpesviruses have been characterized, including several
from
humans, such as herpes simplex virus-1 (HSV-1) and herpes simplex virus-2 (HSV-
2), varicella zoster virus (VZV), Epstein-Barr virus (EBV), cytomegalovirus
(CMV)
and other human herpesviruses such as HHV6 and HHV7. These viruses are
responsible for a variety of human diseases, such as skin infections, genital
herpes,
viral encephalitis, and the like.
HSV-1 infection activates the host defense and innate immune system by
inducing intracellular signaling pathways that lead to the expression of
proteins with
proinflammatory and microbicidal activities, including cytokines and
interferons
(INF) (Sainz and Halford, J. Virol. (2002) 76:11541-11550; Haller et al.,
Virology
(2006) 344:119-130; Paludan et al., Nat. Rev. Immunol. (2011) 11:143-154). INF
signaling is one of the most important cellular defense mechanism for viral
clearance
(Brandner & Mueller, Hoppe-Seyler's ZeitschriftsfUr physiologische Chemie
(1973)
354:1176; De Vries et al., Gene Ther. (2008) 15:545-552).
Investigators have reported antiviral activity of nitric oxide (NO) against
several viruses such as vaccinia virus, vesicular stomatitis virus, and
Japanese
encephalitis virus, among others (Bi et al., J. Virol. (1995) 69:6466-6472;
Harris et
al., J. Virol. (1995) 69:910-915; Lin et al., J. Virol. (1997) 71:5227-5235;
Pertile et
al., Avian Dis. (1996) 40:342-348. NO is a free radical gaseous molecule and
is a
mediator of host defense (Croen K.D., J. Clin. Invest. (1993) 91:2446-2452;
Karupiah et al., Science (1993) 261:1445-1448; Rolph et al., Virol. (1996)
217:470-
477; Amaro et al., J. Med. Virol. (1997) 51:326-331; Lane et al., J. Virol.
(1997)
-1-
CA 02897444 2015-07-07
WO 2014/110053
PCT/US2014/010553
71:2202-2210. HSV-1 is known both to induce and evade host antiviral responses
(Mossman et al., I Virol. (2001) 75:750-758). HSV infection is capable of
inducing
expression of inducible nitric oxide synthase (iNOS), a gene encoding an
inducible
isoform of NOS that produces large amounts of NO.
Herpesviruses and recombinant proteins therefrom have been used in the
manufacture of a number of vaccines. Besides adenoviruses, herpesviruses have
been
shown to provide complete helper virus functions for the production of
recombinant
adeno-associated virus virions (Buller, R.M.L., I Virol. (1981) 40:241-247;
Mishra et
al., Virology (1990) 179:632-639). The minimal set of HSV-lgenes required for
AAV replication and packaging has been identified as the early genes UL5, UL8,
UL52 andUL29 (Weindler et al., I Virol. (1991) 65:2476-2483). These genes
encode
components of the HSV-lcore replication machinery ¨ the helicase, primase and
primase accessory proteins (UL5, UL8 and UL52) and the single-stranded DNA
binding protein (UL29).
Recombinant AAV (rAAV) vectors have been successfully used to achieve
long-term, high level transduction in vivo. Despite the above advances,
production of
large quantities of clinical grade high-titer rAAV virions for gene therapy
continues to
be challenging due to limitations in scalability of the cotransfection
protocol. The
process requires the efficient cellular delivery of three components: (1) a
vector
including the gene of interest flanked by AAV inverted terminal repeats
(ITRs); (2) a
vector including the AAV rep and cap genes; and (3) genes provided using a
helper
virus, such as adenovirus or herpes simplex virus or using virus-free helper
plasmids
(see, Muzyczka, N., Curr. Top. Microbiol. Immunol. (1992) 158:97-129). Thus,
in
rHSV-based rAAV manufacturing protocols, the yield of rAAV is limited by the
maximal titer of helper rHSV vectors.
A replication-deficient HSV-1 vector, termed d27.1-rc, expresses AAV-2 rep
and cap genes (Conway et al., Gene Ther. (1999) 6:986-993) and it has been
engineered from original d27-1 virus (Rice at al., J. Virol. 1989 vol. 63 (8)
pp. 3399-
407), that does not produce ICP27, a protein required for HSV-lreplication.
Although this vector is replication-defective, it does express the HSV-1 early
genes
required for rAAV replication and packaging (Conway et al., Gene Ther. (1999)
6:986-993).
-2-
CA 02897444 2015-07-07
WO 2014/110053
PCT/US2014/010553
Typically, one vector bearing the rAAV template and the other vector
expressing the AAV rep and cap regions are co-infected into 293 cells in order
to
produce rAAV virions. Both HSV-1 vectors are replication-deficient and can
therefore only be propagated in an ICP27-complementing cell line, V27 (Rice at
al., J.
Virol. 1989 vol. 63 (8) pp. 3399-407). In HSV-based AAV production protocol,
293
cells need to be infected with HSV-1 at a higher multiplicity of infection
(MOI) of 12.
This represents a limitation, because yields of d27-1-derived vectors in V27
cells are
typically around 1 X 107 plaque forming units (PFU)/ml.
Several methods and reagents have been investigated in order to further
increase HSV-1 titers (see, e.g., Wechucket al., Biotechnol. Frog. (2000)
16:493-496;
Ozuer et al., Biotechnol. Frog. (2002) 18:476-482; Erlandsson et al., I
Endocrinol.,
(2002) 175:165-176; Otsuki et al., Mol. Ther. (2008) 16:1546-1555). Both
dexamethasone and valproic acid inhibited the host defense mechanism
represented
by several interferon (IFN)-responsive antiviral genes, augmented the
transcriptional
level of viral genes, and thus improved viral propagation and yield of HSV-1
(Erlandsson et al., I EndocrinoL (2002) 175:165-176; Otsuki et al., MoL Ther.
(2008)
16:1546-1555).
Despite the above knowledge, more methods to inhibit host defense in order to
improve viral production in culture are needed. As explained above,
investigators
have reported antiviral activity of nitric oxide (NO) against several viruses
such as
vaccinia virus, vesicular stomatitis virus, and Japanese encephalitis virus,
among
others (Bi et al., J. Virol. (1995) 69:6466-6472; Harris et al., I Viral.
(1995) 69:910-
915; Lin et al., I Virol. (1997) 71:5227-5235; Pertile et al., Avian Dis.
(1996) 40:342-
348. NO is a free radical gaseous molecule and is a mediator of host defense
(Croen
K.D., J. Clin. Invest. (1993) 91:2446-2452; Karupiah et al., Science (1993)
261:1445-
1448; Rolph et al., Virol. (1996) 217:470-477; Amaro et al., J. Med. Virol.
(1997)
51:326-331; Lane etal., I Virol. (1997) 71:2202-2210). As described above, HSV
infection can induce expression of iNOS, a gene encoding an inducible isoform
of
NOS that produces large amounts of NO.
The presence of the iNOS inhibitor N-methyl-L-arginine (L-NMA) reversed
the inhibition of viral replication for all three of these viruses (Karupiah
et al., Science
(1993) 261:1445-1448). For a review of iNOS inhibitors, see, Southan et al.,
Biochem. Pharmacol. (1996) 51:383-394. Another compound, aurintricarboxylic
acid
-3-
CA 02897444 2015-07-07
WO 2014/110053
PCT/US2014/010553
(ATA), has been shown to protect macrophages from cell death induced by
bacterial
lipopolysaccharide by downregulation of iNOS expression and thus decreasing
the
NO production (Chen et al., British Journal of Pharmacology (2002) vol. 137
(7) pp. 1011-
20). ATA is a heterogeneous mixture of polymers accredited with an increasing
number of biological activities, such as interaction with a number of enzymes
including DNA polymerases, RNA polymerases, reverse transcriptase (RNA-
dependent DNA polymerase), aminoacyl-tRNA-synthetase, ribonucleotide
reductase,
ribonucleases nuclease, protein synthesis inhibition, prevention of apoptosis
and
blocking DNA fragmentation in oligodendrocytes induced by oxidative stress
(Tscheme and Pestka, Antimicrob. Agents Chemother.(1975) 8:479-487; Mikelens
et
al., Biochemical Pharmacology (1976) 25:821-827; Vollgraf et al.,
Neurochem. (1999) 73:2501-2509).
Aurintricarboxylic acid (ATA) has been also reported to prevent IFN-
mediated transcriptional activation (Tsi et al., Mol. Pharmacol. (2002)101:90-
101;
Chen et al., Britishi Pharmacol. (2002) 137:1011-1020). ATA is known as an
activator of the Raf/MEK/MAPK pathway, IGF-1 receptor and protein kinase C
signaling (Beery et al., Endocrinology (2001) 142:3098-3107; Chen et al., I
Biol.
Chem. (2001) 276:46722-46728). Antiviral antimicrobial and antiproliferative
actions
of cytokines such as interferons may be due to their ability to induce the
expression of
iNOS, a gene encoding an isoform of nitric oxide synthase (NOS) that produces
large
amounts of the radical gas, NO, from a guanidino nitrogen of L-arginine
(Nathan, C.,
FASAB J. (1992) 6:3051; Werner-Felmayer etal., I Exp. Med. (1990) 172:1599).
It
has been shown that treatment of macrophages with IFN-7 severely restricts
replication of ectromelia virus (EV), vaccinia virus (VV) and HSV-1.
On one hand, ATA is also known as an antiviral agent against several viruses
including HIV, herpesvirus HHV-7, SARS-CoV and others (Cushman et al., I Med.
Chem. (1991) 34:329-3371991; Zhang et al., Antiviral Res. (1999) 43:23-35; Yap
et
al., Computational Biol. and Chem. (2005) 29:212-219; De Clercq, Advents,
Advances, and Adventures Med. Res. Rev. (2011) 31:118-160). ATA, however, did
not block the replication of adenovirus type 5 (Ad5) in HEK-293 cells (He,
Biochem.
Biophys. Res. Comm. (2004) 320:1199-1203). Moreover, ATA has been reported to
unexpectedly increase titer of a control adenovirus vector in 293 cells while
at the
-4-
CA 02897444 2015-07-07
WO 2014/110053
PCT/US2014/010553
same time having antiviral effects on vaccinia virus (Myskiw et al., I Virol.
(2007)
81:3027-3032).
SUMMARY OF THE INVENTION
The present invention thus overcomes deficiencies in the prior art by
addressing problems that limit viral production, such as low production of
rHSV,
which hampers efforts to produce sufficient quantities of rHSV for a variety
of
purposes, including for vaccine production, as well as for rAAV virion
production in
quantities necessary for efficient gene therapy procedures. Using the methods
described herein, higher titers of a variety of viruses can be obtained, such
as at least
an order of magnitude greater than traditional methods.
In particular, the inventors herein have discovered that aurintricarboxylic
acid
(ATA) inhibits iNOS and increases HSV production. As shown in the examples
herein, micromolar concentrations of ATA in the presence of fetal bovine serum
(FBS) increased both HSV-1/d27-1 vector yield in V27 cells and wild-type (wt)
HSV-
1 virus in Vero, V27 and 293 cells. Other iNOS inhibitors, including
dexamethasone
and valproic acid, also increased HSV-1 titers in culture. HSV-induced iNOS
expression was shown to be reduced in HSV+ATA samples as analyzed by
SABiosciences Microarray. Similarly, Affymetrix human genome array analysis
confirmed that expression of HSV-up-regulated all three nitric oxide synthase
genes
(nNOS, iNOS and eNOS) were down-regulated n HSV+ATA samples. Affymetrix
Gene Array also detected that genes involved in inflammatory IgE and IFN
signaling,
and general immune responses were upregulated by HSV-1 and suppressed after
the
addition of ATA. On the other hand, genes primarily involved in cell cycle
Gl/S,
signal transduction in WNT development were significantly down-regulated by
HSV
and upregulated after addition of ATA.
These results are significant because of the demand for higher HSV-1 titers
for
rAAV virion production, as well as for prophylactic, therapeutic and
diagnostic
purposes.
Accordingly, in one embodiment the invention is directed to a method for
producing a virus comprising culturing the virus in a cell culture that
comprises
aurintricarboxylic acid. In certain embodiments, the virus is a herpesvirus,
such as
HSV-1.
-5-
CA 02897444 2015-07-07
WO 2014/110053
PCT/US2014/010553
In additional embodiments, the herpesvirus is a wild type HSV-1 or a
recombinant HSV-1 vector, such as an HSV-1 d27.1 vector.
In further embodiments, the virus is cultured in 293, HeLa or Vero cells, such
as V27 cells.
In yet additional embodiments, the invention is directed to a method for
culturing an HSV-1 d27.1 vector comprising:
(a) infecting V27 cells with an HSV-1 d27.1 vector; and
(b) culturing the infected V27 cells in a cell culture comprising
aurintricarboxylic acid, valproic acid or dexamethasone.
In certain embodiments, the cell culture further comprises serum, such as
fetal
bovine serum.
In further embodiments, the invention is directed to a cell culture comprising
aurintricarboxylic acid and 293, HeLa or Vero cells, such as V27 cells.
These and other embodiments of the subject invention will readily occur to
those of skill in the art in view of the disclosure herein.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1 is a representation of a Western blot showing that aurintricarboxylic
acid (ATA) inhibits iNOS expression in d27-1-infected V27 lysates.
Figures 2A-2C show the ATA-HSV protocol rationale (Figure 2A) and the
optimization of d27-1 HSV-1 titers in V27 supernatants in order to determine
which
concentrations and conditions for ATA addition have impact on HSV yields.
Figure
2B shows viral titers expressed as DNase resistant particles (DRP/ml) at
various ATA
concentrations in six well plates (Figure 2B) and T150 flasks (Figure 2C).
Figure 3 shows the importance of serum presence in ATA-HSV protocol.
Additional optimization and the importance of FBS presence in ATA-HSV protocol
was shown on d27-1 HSV-1 titers expressed as drp/ml and pfu/ml.
Figures 4A-4B show the effect of ATA on wild type HSV KOS and McIntyre
strains in culture. ATA increased the yield of both virus types in Vero cells,
however,
ATA appeared to inhibit HSV-1 KOS growth in 293 cells. On the other hand,
wtHSV-1 McIntyre strain reached the highest titers after ATA induction in 293
cells.
Moreover, ATA appeared to inhibit BOTH types of HSV-1 viruses in HeLa cells.
-6-
CA 02897444 2015-07-07
WO 2014/110053
PCT/US2014/010553
Figures 5A-5B show the effect of ATA in HSV stocks on the production of
rAAV Virions. rAAV titers were slightly increased when using the HSV stock
prepared with 2011M ATA added during infection. ATA was also shown to increase
rAAV titer when 10 .1\4 ATA was spiked directly into 293 cell media during 2
hrs of
the HSV coinfection step.
Figure 6 shows the effect of dexamethasone (Dex) on d27-1/GFP HSV-1 viral
titer. The final titers d27-1/GFP HSV-1 were, in general, slightly elevated
after dex
pretreatments or treatments as compared to untreated control.
Figure 7 shows the effect of pretreatment by valproic acid (VA) on d27-1/GFP
HSV-1 viral titer. VA at a concentration 5 mM slightly elevated the titer of
d27-
1/GFP HSV-1, however the concentrations bellow and above of 5 mM appeared to
have an inhibitory effect on d27-1/GFP HSV-1 titer, as compared to untreated
control.
DETAILED DESCRIPTION OF THE INVENTION
The practice of the present invention will employ, unless otherwise indicated,
conventional methods of chemistry, biochemistry, recombinant DNA techniques
and
immunology, within the skill of the art. Such techniques are explained fully
in the
literature. See, e.g., Fundamental Virology, 2nd Edition, vol. I & II (B.N.
Fields and
D.M. Knipe, eds.); Handbook of Experimental Immunology,Vols. I-TV (D.M. Weir
and C.C. Blackwell eds., Blackwell Scientific Publications); T.E. Creighton,
Proteins:
Structures and Molecular Properties (W.H. Freeman and Company, 1993); A.L.
Lehninger, Biochemistry (Worth Publishers, Inc., current addition); Sambrook,
et al.,
Molecular Cloning: A Laboratory Manual (2nd Edition, 1989); Methods In
Enzymology (S. Colowick and N. Kaplan eds., Academic Press, Inc.).
All publications, patents and patent applications cited herein, whether supra
or
infra, are hereby incorporated by reference in their entirety.
1. DEFINITIONS
In describing the present invention, the following terms will be employed, and
are intended to be defined as indicated below.
It must be noted that, as used in this specification and the appended claims,
the
singular forms "a", "an" and "the" include plural referents unless the content
clearly
-7-
CA 02897444 2015-07-07
WO 2014/110053
PCT/US2014/010553
dictates otherwise. Thus, for example, reference to "a herpesvirus" includes a
mixture
of two or more such viruses, and the like.
The terms "recombinant HSV," "rHSV," and "rHSV vector" refer to isolated,
genetically modified forms of herpes simplex virus (HSV) containing
heterologous
genes incorporated into the viral genome. By the term "rHSV/rc" or "rHSV/rc
virus"
or "rHSV helper function vector" is meant a rHSV in which the AAV rep and/or
cap
genes have been incorporated into the rHSV genome. The terms "rHSV expression
virus," and "rHSV/AAV" denote a rHSV in which inverted terminal repeat (ITR)
sequences from AAV have been incorporated into the rHSV genome.
The terms "polypeptide" and "protein" refer to a polymer of amino acid
residues and are not limited to a minimum length of the product. Thus,
peptides,
oligopeptides, dimers, multimers, and the like, are included within the
definition.
Both full-length proteins and fragments thereof are encompassed by the
definition.
The terms also include postexpression modifications of the polypeptide, for
example,
glycosylation, acetylation, phosphorylation and the like. Furthermore, for
purposes of
the present invention, a "polypeptide" refers to a protein which includes
modifications, such as deletions, additions and substitutions (generally
conservative in
nature), to the native sequence, so long as the protein maintains the desired
activity.
These modifications may be deliberate, as through site-directed mutagenesis,
or may
be accidental, such as through mutations of hosts which produce the proteins
or errors
due to PCR amplification. Depending on the expression system used, a
polypeptide
may include or lack an N-terminal methionine. Additionally, a polypeptide may
or
may not include the native signal sequence, if one is naturally present. If a
signal
sequence is not normally present, the protein can be produced with a
heterologous
sequence.
A "native" polypeptide refers to a polypeptide having the same amino acid
sequence as the corresponding molecule derived from nature. Such native
sequences
can be isolated from nature or can be produced by recombinant or synthetic
means.
The term "native" sequence specifically encompasses naturally-occurring
truncated or
secreted forms of the specific molecule (e.g., an extracellular domain
sequence),
naturally-occurring variant forms (e.g., alternatively spliced forms) and
naturally-
occurring allelic variants of the polypeptide.
-8-
CA 02897444 2015-07-07
WO 2014/110053
PCT/US2014/010553
By "variant" is meant an active polypeptide as defined herein having at least
about 80% amino acid sequence identity with the corresponding full-length
native
sequence, a polypeptide lacking the signal peptide, an extracellular domain of
a
polypeptide, with or without a signal peptide, or any other fragment of a full-
length
polypeptide sequence as disclosed herein. Such polypeptide variants include,
for
instance, polypeptides wherein one or more amino acid residues are added, or
deleted,
at the N- and/or C-terminus of the full-length native amino acid sequence.
Ordinarily,
a variant will have at least about 80% amino acid sequence identity,
alternatively at
least about 81% amino acid sequence identity, alternatively at least about 82%
amino
acid sequence identity, alternatively at least about 83% amino acid sequence
identity,
alternatively at least about 84% amino acid sequence identity, alternatively
at least
about 85% amino acid sequence identity, alternatively at least about 86% amino
acid
sequence identity, alternatively at least about 87% amino acid sequence
identity,
alternatively at least about 88% amino acid sequence identity, alternatively
at least
about 89% amino acid sequence identity, alternatively at least about 90% amino
acid
sequence identity, alternatively at least about 91% amino acid sequence
identity,
alternatively at least about 92% amino acid sequence identity, alternatively
at least
about 93% amino acid sequence identity, alternatively at least about 94% amino
acid
sequence identity, alternatively at least about 95% amino acid sequence
identity,
alternatively at least about 96% amino acid sequence identity, alternatively
at least
about 97% amino acid sequence identity, alternatively at least about 98% amino
acid
sequence identity and alternatively at least about 99% amino acid sequence
identity to
the corresponding full-length native sequence. Ordinarily, variant
polypeptides are at
least about 10 amino acids in length, such as at least about 20 amino acids in
length,
e.g., at least about 30 amino acids in length, alternatively at least about 40
amino
acids in length, alternatively at least about 50 amino acids in length,
alternatively at
least about 60 amino acids in length, alternatively at least about 70 amino
acids in
length, alternatively at least about 80 amino acids in length, alternatively
at least
about 90 amino acids in length, alternatively at least about 100 amino acids
in length,
alternatively at least about 150 amino acids in length, alternatively at least
about 200
amino acids in length, alternatively at least about 300 amino acids in length,
or more.
Particularly preferred variants include substitutions that are conservative in
nature, i.e., those substitutions that take place within a family of amino
acids that are
-9-
CA 02897444 2015-07-07
WO 2014/110053
PCT/US2014/010553
related in their side chains. Specifically, amino acids are generally divided
into four
families: (1) acidic -- aspartate and glutamate; (2) basic -- lysine,
arginine, histidine;
(3) non-polar -- alanine, valine, leucine, isoleucine, proline, phenylalanine,
methionine, tryptophan; and (4) uncharged polar -- glycine, asparagine,
glutamine,
cysteine, serine threonine, tyrosine. Phenylalanine, tryptophan, and tyrosine
are
sometimes classified as aromatic amino acids. For example, it is reasonably
predictable that an isolated replacement of leucine with isoleucine or valine,
an
aspartate with a glutamate, a threonine with a serine, or a similar
conservative
replacement of an amino acid with a structurally related amino acid, will not
have a
major effect on the biological activity. For example, the polypeptide of
interest may
include up to about 5-10 conservative or non-conservative amino acid
substitutions, or
even up to about 15-25 or 50 conservative or non-conservative amino acid
substitutions, or any number between 5-50, so long as the desired function of
the
molecule remains intact.
"Homology" refers to the percent identity between two polynucleotide or two
polypeptide moieties. Two DNA, or two polypeptide sequences are "substantially
homologous" to each other when the sequences exhibit at least about 50%,
preferably
at least about 75%, more preferably at least about 80%-85%, preferably at
least about
90%, and most preferably at least about 95%-98% sequence identity over a
defined
length of the molecules. As used herein, substantially homologous also refers
to
sequences showing complete identity to the specified DNA or polypeptide
sequence.
In general, "identity" refers to an exact nucleotide-to-nucleotide or amino
acid-to-amino acid correspondence of two polynucleotides or polypeptide
sequences,
respectively. Percent identity can be determined by a direct comparison of the
sequence information between two molecules by aligning the sequences, counting
the
exact number of matches between the two aligned sequences, dividing by the
length
of the shorter sequence, and multiplying the result by 100. Readily available
computer programs can be used to aid in the analysis, such as ALIGN, Dayhoff,
M.O.
in Atlas of Protein Sequence and Structure M.O. Dayhoff ed., 5 Suppl. 3:353-
358,
National Biomedical Research Foundation, Washington, DC, which adapts the
local
homology algorithm of Smith and Waterman Advances in Appl. Math.2:482-489,
1981 for peptide analysis. Programs for determining nucleotide sequence
identity are
available in the Wisconsin Sequence Analysis Package, Version 8 (available
from
-10-
CA 02897444 2015-07-07
WO 2014/110053
PCT/US2014/010553
Genetics Computer Group, Madison, WI) for example, the BESTFIT, FASTA and
GAP programs, which also rely on the Smith and Waterman algorithm. These
programs are readily utilized with the default parameters recommended by the
manufacturer and described in the Wisconsin Sequence Analysis Package referred
to
above. For example, percent identity of a particular nucleotide sequence to a
reference sequence can be determined using the homology algorithm of Smith and
Waterman with a default scoring table and a gap penalty of six nucleotide
positions.
Another method of establishing percent identity in the context of the present
invention is to use the MPSRCH package of programs copyrighted by the
University
of Edinburgh, developed by John F. Collins and Shane S. Sturrok, and
distributed by
IntelliGenetics, Inc. (Mountain View, CA). From this suite of packages the
Smith-Waterman algorithm can be employed where default parameters are used for
the scoring table (for example, gap open penalty of 12, gap extension penalty
of one,
and a gap of six). From the data generated the "Match" value reflects
"sequence
identity." Other suitable programs for calculating the percent identity or
similarity
between sequences are generally known in the art, for example, another
alignment
program is BLAST, used with default parameters. For example, BLASTN and
BLASTP can be used using the following default parameters: genetic code =
standard;
filter = none; strand = both; cutoff= 60; expect = 10; Matrix = BLOSUM62;
Descriptions = 50 sequences; sort by = HIGH SCORE; Databases = non-redundant,
GenBank + EMBL + DDBJ + PDB + GenBank CDS translations + Swiss protein +
Spupdate + PIR. Details of these programs are well known in the art.
Alternatively, homology can be determined by hybridization of
polynucleotides under conditions which form stable duplexes between homologous
regions, followed by digestion with single-stranded-specific nuclease(s), and
size
determination of the digested fragments. DNA sequences that are substantially
homologous can be identified in a Southern hybridization experiment under, for
example, stringent conditions, as defined for that particular system. Defining
appropriate hybridization conditions is within the skill of the art. See,
e.g., Sambrook
et al., supra; DNA Cloning, supra; Nucleic Acid Hybridization, supra.
By the term "degenerate variant" is intended a polynucleotide containing
changes in the nucleic acid sequence thereof, that encodes a polypeptide
having the
-11-
CA 02897444 2015-07-07
WO 2014/110053
PCT/US2014/010553
same amino acid sequence as the polypeptide encoded by the polynucleotide from
which the degenerate variant is derived.
A "coding sequence" or a sequence which "encodes" a selected polypeptide, is
a nucleic acid molecule which is transcribed (in the case of DNA) and
translated (in
the case of mRNA) into a polypeptide in vivo when placed under the control of
appropriate regulatory sequences. The boundaries of the coding sequence are
determined by a start codon at the 5' (amino) terminus and a translation stop
codon at
the 3' (carboxy) terminus. A transcription termination sequence may be located
3' to
the coding sequence.
By "vector" is meant any genetic element, such as a plasmid, phage,
transposon, cosmid, chromosome, virus, virion, etc., which is capable of
replication
when associated with the proper control elements and which can transfer gene
sequences to cells. Thus, the term includes cloning and expression vehicles,
as well
as viral vectors.
By "recombinant vector" is meant a vector that includes a heterologous
nucleic acid sequence which is capable of expression in vivo.
By "recombinant virus" is meant a virus that has been genetically altered,
e.g.,
by the addition or insertion of a heterologous nucleic acid construct into the
particle.
The term "transgene" refers to a polynucleotide that is introduced into a cell
and is capable of being transcribed into RNA and optionally, translated and/or
expressed under appropriate conditions. In one aspect, it confers a desired
property to
a cell into which it was introduced, or otherwise leads to a desired
therapeutic or
diagnostic outcome.
The terms "genome particles (gp)," and "genome equivalents," as used in
reference to a viral titer, refer to the number of virions containing the
recombinant
AAV DNA genome, regardless of infectivity or functionality. The number of
genome
particles in a particular vector preparation can be measured by procedures
known in
the art, such as described in for example, in Clark et al., Hum. Gene Ther.
(1999)
10:1031-1039; and Veldwijk et al., Mol. Ther. (2002) 6:272-278.
The terms "infection unit (iu)," "infectious particle," or "replication unit,"
as
used in reference to a viral titer, refer to the number of infectious
recombinant AAV
vector particles as measured by the infectious center assay, also known as
replication
-12-
CA 02897444 2015-07-07
WO 2014/110053
PCT/US2014/010553
center assay, as described, for example, in McLaughlin et al., J. Virol.
(1988)
62:1963-1973.
The term "transducing unit (tu)" as used in reference to a viral titer, refers
to
the number of infectious recombinant AAV vector particles that result in the
production of a functional transgene product as measured in functional assays
such as
described in, for example, in Xiao et al., Exp. Neurobiol. (1997) 144:1 13-
124; or in
Fisher et al., J. Virol. (1996) 70:520-532 (LFU assay).
The term "transfection" is used to refer to the uptake of foreign DNA by a
cell,
and a cell has been "transfected" when exogenous DNA has been introduced
inside
the cell membrane. A number of transfection techniques are generally known in
the
art. See, e.g., Graham et al. (1973) Virology, 52 :456, Sambrook et al. (1989)
Molecular Cloning, a laboratory manual, Cold Spring Harbor Laboratories, New
York, Davis et al. (1986) Basic Methods in Molecular Biology, Elsevier, and
Chu et
al. (1981) Gene13:197. Such techniques can be used to introduce one or more
exogenous DNA moieties into suitable host cells.
The term "heterologous" as it relates to nucleic acid sequences such as coding
sequences and control sequences, denotes sequences that are not normally
joined
together, and/or are not normally associated with a particular cell. Thus, a
"heterologous" region of a nucleic acid construct or a vector is a segment of
nucleic
acid within or attached to another nucleic acid molecule that is not found in
association with the other molecule in nature. For example, a heterologous
region of
a nucleic acid construct could include a coding sequence flanked by sequences
not
found in association with the coding sequence in nature. Another example of a
heterologous coding sequence is a construct where the coding sequence itself
is not
found in nature (e.g., synthetic sequences having codons different from the
native
gene). Similarly, a cell transformed with a construct which is not normally
present in
the cell would be considered heterologous for purposes of this invention.
Allelic
variation or naturally occurring mutational events do not give rise to
heterologous
DNA, as used herein.
A "nucleic acid" sequence refers to a DNA or RNA sequence. The term
captures sequences that include any of the known base analogues of DNA and RNA
such as, but not limited to 4-acetylcytosine, 8-hydroxy-N6-methyladenosine,
aziridinylcytosine, pseudoisocytosine, 5-(carboxyhydroxyl-methyl) uracil,
-13-
CA 02897444 2015-07-07
WO 2014/110053
PCT/US2014/010553
5-fluorouracil, 5-bromouracil, 5-carboxymethylaminomethy1-2-thiouracil, 5-
carboxymethyl-aminomethyluracil, dihydrouracil, inosine, N6-
isopentenyladenine, 1-
methyladenine, 1-methylpseudo-uracil, 1-methylguanine, 1-methylinosine,
2,2-dimethyl-guanine, 2-methyladenine, 2-methylguanine, 3-methyl-cytosine, 5-
methylcytosine, N6-methyladenine, 7-methylguanine, 5-methylaminomethyluracil,
5-methoxy-amino-methy1-2-thiouracil, beta-D-mannosylqueosine, 5'-
methoxycarbonylmethyluracil, 5-methoxyuracil, 2-methylthio-N6-
isopentenyladenine, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic
acid,
oxybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil,
2-thiouracil, 4-thiouracil, 5-methyluracil, ¨uracil-5-oxyacetic acid
methylester, uracil-
5-oxyacetic acid, pseudouracil, queosine, 2-thiocytosine, and 2,6-
diaminopurine.
The term DNA "control sequences" refers collectively to promoter sequences,
polyadenylation signals, transcription termination sequences, upstream
regulatory
domains, origins of replication, internal ribosome entry sites ("IRES"),
enhancers, and
the like, which collectively provide for the replication, transcription and
translation of
a coding sequence in a recipient cell. Not all of these control sequences need
always
be present so long as the selected coding sequence is capable of being
replicated,
transcribed and translated in an appropriate host cell.
The term "promoter" is used herein in its ordinary sense to refer to a
nucleotide region comprising a DNA regulatory sequence, wherein the regulatory
sequence is derived from a gene which is capable of binding RNA polymerase and
initiating transcription of a downstream (3'-direction) coding sequence.
Transcription
promoters can include "inducible promoters" (where expression of a
polynucleotide
sequence operably linked to the promoter is induced by an analyte, cofactor,
regulatory protein, etc.), "repressible promoters" (where expression of a
polynucleotide sequence operably linked to the promoter is induced by an
analyte,
cofactor, regulatory protein, etc.), and "constitutive promoters".
"Operably linked" refers to an arrangement of elements wherein the
components so described are configured so as to perform their usual function.
Thus,
control sequences operably linked to a coding sequence are capable of
effecting the
expression of the coding sequence. The control sequences need not be
contiguous
with the coding sequence, so long as they function to direct the expression
thereof.
Thus, for example, intervening untranslated yet transcribed sequences can be
present
-14-
CA 02897444 2015-07-07
WO 2014/110053
PCT/US2014/010553
between a promoter sequence and the coding sequence and the promoter sequence
can
still be considered "operably linked" to the coding sequence.
By "isolated" when referring to a protein or nucleotide sequence, is meant
that
the indicated molecule is present in the substantial absence of other
biological
macromolecules of the same type. Thus, for example, an "isolated nucleic acid
molecule which encodes a particular polypeptide" refers to a nucleic acid
molecule
which is substantially free of other nucleic acid molecules that do not encode
the
subject polypeptide; however, the molecule may include some additional bases
or
moieties which do not deleteriously affect the basic characteristics of the
composition.
For the purpose of describing the relative position of nucleotide sequences in
a
particular nucleic acid molecule throughout the instant application, such as
when a
particular nucleotide sequence is described as being situated "upstream,"
"downstream," "3-prime (3')" or "5-prime (5')" relative to another sequence,
it is to
be understood that it is the position of the sequences in the "sense" or
"coding" strand
of a DNA molecule that is being referred to as is conventional in the art.
The term "about", particularly in reference to a given quantity, is meant to
encompass deviations of plus or minus five percent.
2. MODES OF CARRYING OUT THE INVENTION
Before describing the present invention in detail, it is to be understood that
this
invention is not limited to particular formulations or process parameters as
such may,
of course, vary. It is also to be understood that the terminology used herein
is for the
purpose of describing particular embodiments of the invention only, and is not
intended to be limiting.
Although a number of methods and materials similar or equivalent to those
described herein can be used in the practice of the present invention, the
preferred
materials and methods are described herein.
Central to the present invention is the discovery that aurintricarboxylic acid
(ATA) in micromolar concentrations increases HSV-1 vector yield. This finding
is
important for both large-scale HSV production, as well as rHSV and rAAV vector
production. Moreover and surprisingly, as shown in the examples, the presence
of
ATA in rHSV-1 stocks did not negatively influence rAAV yield. This result is
surprising as ATA in millimolar amounts and higher concentrations is known to
be an
-15-
CA 02897444 2015-07-07
WO 2014/110053
PCT/US2014/010553
antiviral agent (Cushman et al., Med. Chem. (1991) 34:329-337; Zhang et al.,
Antiviral Res. (1999) 43:23-35; Yap et al., Computational Biol. and Chem.
(2005)
29:212-219; De Clercq, Advents, Advances, and Adventures Med. Res. Rev. (2011)
31:118-160).
As explained above, investigators have reported antiviral activity of nitric
oxide (NO) against several viruses such as vaccinia virus, vesicular
stomatitis virus,
and Japanese encephalitis virus, among others (Bi et al., I Virol. (1995)
69:6466-
6472; Harris etal., ./ Virol. (1995) 69:910-915; Lin et al., 1997; Pertile et
al., Avian
Dis. (1996) 40:342-348). NO is a free radical gaseous molecule is a mediator
of host
defense (Croen K.D., I Clin. Invest. (1993) 91:2446-2452; Karupiah et al.,
Science
(1993) 261:1445-1448; Rolph etal., Virol. (1996) 217:470-477; Amaro et al., I
Med.
Virol. (1997) 51:326-331; Lane et al., I Virol. (1997) 71:2202-2210). HSV
infection
is capable of inducing the expression of inducible nitric oxide synthase
(iNOS), a
gene encoding an inducible isoform of NOS that produces large amounts of NO.
As shown herein, ATA suppresses HSV-up-regulated iNOS and thereby
increases HSV titers in culture. Additional iNOS inhibitors, including
dexamethasone
and valproic acid, also have the same effect. In one embodiment, then, the use
of
such iNOS inhibitors increases recombinant herpesvirus titers in culture,
allowing the
production of significantly more virus than produced in the absence of the
particular
inhibitor. Viruses produced by the method can be used in a variety of
contexts,
including for prophylactic, therapeutic and diagnostic purposes, as well as
for
producing recombinant constructs in sufficient quantity to use in the
preparation of
recombinant virions for gene delivery and gene therapy.
Aurintricarboxylic acid (ATA), 5-((3-carboxy-4-hydroxyphenyl)(3-carboxy-4-
oxo-2,5-cyclohexadien-1-ylidene)methyl)-2-hydroxybenzoic acid, is a
heterogeneous
mixture of nonsulfated negatively-charged aromatic polymers that forms when
salicylic acid is treated with formaldehyde, sulfuric acid and sodium nitrite
(see
Cushman, et al., (1991) I Med. Chem.34:329-337; Cushman, et al., I Med. Chem.
34:337-342). Aurintricarboxylic acid has the formula:
-16-
CA 02897444 2015-07-07
WO 2014/110053
PCT/US2014/010553
0
COOH
COOH
0
OH
The heterogeneous mixture of ATA was described to inhibit protein nucleic
acid interactions (Gonzalezet al., Biochim. Biophys. Acta, (1979) 562:534-
545); to
interact with steroid receptors at the nuclear uptake and the nuclear binding
levels
(Mellon, W. S., Biochem. Pharmacol. (1984) 33:1047-1057; Moudgilet al., J.
Steroid
Biochem. (1985) 23:125-132); to inhibit DNA polymerase (Nakaneet al.,Eur. J.
Biochem. (1988) 177:91-96); and to act as a RNAase inhibitor (Skidmoreet al.,
Biochem. J.(1989) 263:73-80).
ATA for addition to virus in culture can be used in the acidic form or can be
provided as a salt, such as aurintricarboxylic acid trisodium salt; calcium
salt;
ammonium salt, etc.
Additional substances that will find use with the present methods include
dexamethasone (Dex) and valproic acid (VA). Dex has been shown to inhibit iNOS
expression in rat mesangial cells at transcriptional and post-transcriptional
levels
(Kunz et al., Biochem. 1 (1994) 304:337-340; Kunz et al., Proc. Natl. Acad.
Sci. USA
(1996) 93:255-259). Dex has also been shown to enhance HSV-1 oriL DNA
replication in PC12 cells. Sodium valproate, the sodium salt of VA, has been
shown
to stimulate replication of HSV-1, human cytomegalovirus, HIF-1, human herpes
virus-8, measles virus and poliovirus type 1 (Motamedifar et al., Iran. J.
Med. Sci.
(2006) 31:28-32; Kuntz-Simon et al., J. Gen. Virol (1995) 76:1409-1415; Moog
etal.,
J. Gen. Virol (1996) 77:1993-1999; Ylisastigui et al., AIDS (2004) 18:1101-
1108;
Shaw et al., AIDS (2000) 14:899-902; Kabiri et al. Iran J. Med. Sci. (2001)
26:55-61).
Additionally, valproic acid has been shown to inhibit iNOS (Guo et al.,
Surgery
(2007) 142:156-162). As with ATA, VA, or its salts, such as sodium, calcium,
ammonium salts, etc., can be used in the present methods.
-17-
CA 02897444 2015-07-07
WO 2014/110053
PCT/US2014/010553
Although the use of ATA, Dex, and VA to produce rHSV-1 vectors at higher
titers is exemplified herein, these iNOS inhibitors can be used to increase
the titer of a
variety of viruses in culture, such as but not limited to viruses of the
families
Adenoviridae, Picornaviridae (e.g., polioviruses, etc.); Caliciviridae;
Togaviridae
(e.g., rubella virus, dengue virus, etc.); Flaviviridae; Coronaviridae;
Reoviridae;
Birnaviridae; Rhabodoviridae (e.g., rabies virus, etc.); Poxviridae;
Filoviridae;
Paramyxoviridae (e.g., mumps virus, measles virus, respiratory syncytial
virus, etc.);
Orthomyxoviridae (e.g., influenza virus types A, B and C, etc.); Bunyaviridae;
Arenaviridae; the various hepatitis viruses, such as HAY, HBV and HCV;
papilloma
viruses and rotaviruses; retroviruses; etc. See, e.g. Virology, 3rd Edition
(W.K.
Joklik ed. 1988); Fundamental Virology, 2nd Edition (B.N. Fields and D.M.
Knipe,
eds. 1991), for a description of these and other viruses. These viruses, or
immunogens derived therefrom, can be used in the production of vaccines and
diagnostics. Moreover, some of these viruses, and in particular, the
herpesviruses,
can be used to produce recombinant vectors for the production of recombinant
virions
for use in gene delivery techniques described below.
Thus, ATA, Dex and VA can be used to increase the yield of any of the
herpesviruses that are members of the family herpesviridae. This includes
equine
herpes virus, bovine herpes virus (BHV) and human herpes simplex virus (HSV)
types 1 and 2, such as BHV-1, BHV-2, HSV-1 and HSV-2, varicella zoster virus
(VZV), Epstein-Barr virus (EBV), cytomegalovirus (CMV), HHV6 and HHV7,
among others. The herpesviruses can be derived from any of the many strains.
For
example, when the virus produced using the invention is HSV, the virus may be
derived from, for example, HSV-1 or HSV-2, and may be from any of the various
HSV strains, such as HSV-1 strain KOS, HSV-1 strain McIntyre, HSV-1 strain
Patton, HSV-2 strain 333, HSV-2 strain G, and the like. Moreover, the viruses
produced may be either wild-type viruses, or derivatives thereof, including
recombinant viruses and inter-type recombinants containing DNA from HSV-1 and
HSV-2. Derivatives preferably have at least 70% sequence homology to either
the
HSV-1 or HSV-2 genomes or portions thereof, more preferably at least 80%, even
more preferably at least 90 or 95%. A derivative may have the sequence of a
HSV-1
or HSV-2 genome modified by nucleotide substitutions, for example from 1, 2 or
3 to
10, 25, 50 or 100 substitutions. The HSV-1 or HSV-2 genome may alternatively
or
-18-
CA 02897444 2015-07-07
WO 2014/110053
PCT/US2014/010553
additionally be modified by one or more insertions and/or deletions and/or by
an
extension at either or both ends.
Other derivatives include strains that already have mutations in genes,
particularly mutations in genes that result in attenuation of the virus.
Examples of
such viruses include strain 1716 (MacLean et al., J. Gen. Virol. (1991) 72:632-
639),
strains R3616 and R4009 (Chou and Roizman, Proc. Natl. Acad. Sci USA (1992)
89:
3266-3270) and R930 (Chou et al., J. ViroL (1994) 68:8304-8311) all of which
have
mutations in ICP34.5, strain d120 which has a deletion in ICP4 (DeLuca et
al.,J.
ViroL (1985) 56:558-570), strain d27-1 (Rice and Knipe, J. ViroL (1990)
64:1704-
1715) which has a deletion in ICP27) or strain d92 which has deletions in both
ICP27
and ICP4 (Samaniego etal., I ViroL (1995) 69:5705-5715). The terminology used
in
describing the various HSV genes is as found in, e.g., Coffin and Latchman
(1996),
In: Genetic Manipulation of the Nervous System (DS Latchman Ed.) pp 99-114:
Academic Press, London.
As is readily apparent, any rHSV suitable for the intended purpose can be used
in the invention. In certain embodiments, the rHSV used in the invention is
replication-defective. For the production of rAAV virions, infection of
producer cells
with rHSV that is incapable of replication is preferred because in contrast to
methods
involving use of adenovirus, the rHSV does not become a significant
contaminant of
the rAAV product. This can serve to increase the final yield of rAAV virions
by
eliminating purification steps associated with removal of adenovirus. In a
particular
embodiment of the invention, the rHSV is constructed from a mutant of HSV-1 in
which the inability to replicate is due to a deletion in the ICP27 gene. Any
other
suitable mutants of HSV exhibiting a replication-defective phenotype can also
be used
to construct the rHSV.
One particularly preferred recombinant mutant HSV-1 strain for rAAV
production using the subject methods is HSV-1 strain d27-1. This strain can be
prepared as described in e.g., Conway et al., Gene Ther. (1999) 6:973 985 and
U.S.
Patent No. 7,091,029, incorporated herein by reference in its entirety. As
explained
above, this mutant vector does not produce ICP27 and is advantageously used to
produce rAAV virions as host cell splicing of messenger RNA is known to be
inhibited by ICP27. ICP27 may also effect appropriate splicing of the AAV-2
rep and
cap messages. This vector is replication defective and shows reduced
cytotoxicity
-19-
CA 02897444 2015-07-07
WO 2014/110053
PCT/US2014/010553
compared with wild type (wt) HSV-1. The virus d27-1 displays several other
features
that are advantageous for use as a helper virus for rAAV virion production.
First, it
expresses the early genes known to be required for rAAV production (Weindler
et al.,
Virol. (1991) 65:2476-2483). In addition, d27.1 over-expresses ICP8, the
single-
stranded DNA binding protein that is the product of UL29, one of the HSV-1
genes
essential for AAV replication and packaging (Weindler et al., J. Virol. (1991)
65:2476-2483).
The AAV genome is a linear, single-stranded DNA molecule containing about
4681 nucleotides. The AAV genome generally comprises an internal, nonrepeating
genome flanked on each end by inverted terminal repeats (ITRs). The ITRs are
approximately 145 base pairs (bp) in length. The ITRs have multiple functions,
including providing origins of DNA replication, and packaging signals for the
viral
genome. The internal nonrepeated portion of the genome includes two large open
reading frames, known as the AAV replication (rep) and capsid (cap) genes. The
rep
and cap genes code for viral proteins that allow the virus to replicate and
package into
a virion. In particular, a family of at least four viral proteins are
expressed from the
AAV rep region, Rep 78, Rep 68, Rep 52, and Rep 40, named according to their
apparent molecular weight. The AAV cap region encodes at least three proteins,
VPI,
VP2, and VP3.
By "AAV rep coding region" is meant the art-recognized region of the AAV
genome which encodes the replication proteins Rep 78, Rep 68, Rep 52 and Rep
40.
These Rep expression products have been shown to possess many functions,
including
recognition, binding and nicking of the AAV origin of DNA replication, DNA
helicase activity and modulation of transcription from AAV (or other
heterologous)
promoters. The Rep expression products are collectively required for
replicating the
AAV genome. For a description of the AAV rep coding region, see, e.g.,
Muzyczka,
N. (1992) Current Topics in Microbiol. and Immuno1.158:97-129; and Kotin, R.M.
(1994) Human Gene Therapy5:793-801. Suitable homologues of the AAV rep
coding region include the human herpesvirus 6 (HHV-6) rep gene which is also
known to mediate AAV-2 DNA replication (Thomson et al. (1994)
Virology204:304-311).
By "AAV cap coding region" is meant the art-recognized region of the AAV
genome which encodes the capsid proteins VP1, VP2, and VP3, or functional
-20-
CA 02897444 2015-07-07
WO 2014/110053
PCT/US2014/010553
homologues thereof. These Cap expression products supply the packaging
functions
which are collectively required for packaging the viral genome. For a
description of
the AAV cap coding region, see, e.g., Muzyczka, N. and Kotin, R.M. (supra).
Typically two rHSV vectors will be used to produce rAAV virions. One is a
rHSV helper function vector in which the AAV rep and/or cap genes have been
incorporated into the rHSV genome. The other is a rHSV expression vector in
which
ITR sequences from AAV have been incorporated into the rHSV genome and flank a
gene of interest.
Thus, in one embodiment, the iNOS inhibitor can be used to increase the yield
of a first rHSV vector that contains the AAV rep and/or cap genes. Embodiments
of
the first rHSV vector of the method include but are not limited to gene
constructs
based on the cap gene found in various serotypes of AAV including AAV-1, AAV-
2,
AAV-3, AAV-4, AAV-5 and AAV-6, AAV-7 and AAV-8, caprine and bovine AAV
(see, e.g., U.S. Publ. No. 20080292595, incorporated herein by reference in
its
entirety), and variants thereof Also within the scope of the invention are rep
and cap
genes from novel AAV serotypes, and those modified by recombination or
mutation
of existing serotypes. The rep and cap genes of the AAV helper function vector
can
be derived from any of the known AAV serotypes, as explained above. For
example,
the rHSV helper function vector may have a rep gene derived from AAV-2 and a
cap
gene derived from AAV-6; one of skill in the art will recognize that other rep
and cap
gene combinations are possible, the defining feature being the ability to
support
rAAV virion production.
In certain embodiments, the AAV rep and cap genes in the rHSV helper
function vector may be driven by their native promoters. The p5 and p19
promoters
of AAV-2 control expression of Rep 78 and 68 and Rep 52 and 40, respectively.
The
p40 promoter controls expression of VP1, VP2 and VP3. Additionally,
heterologous
promoters may be used to drive expression of the AAV genes. Examples of other
promoters that can be used in the disclosed methods include but are not
limited to the
SV40 early promoter, CMV promoter, HSV-1 thymidine kinase (HSV-1 tk) promoter,
metallothionine inducible promoter, mouse mammary tumor virus promoter and
chicken 13-actin promoter.
The gene construct can be inserted into any site or sites in the HSV genome
suitable for integration of the rep and cap genes. In certain embodiments, the
vector
-21-
CA 02897444 2015-07-07
WO 2014/110053
PCT/US2014/010553
is constructed by homologous recombination of the AAV rep and cap genes into
the
thymidine kinase (tk) locus of the rHSV-1 virus, as described in Conway et
al., Gene
Ther. (1999) 6:986-993 and U.S. Patent No. 7,091,029, incorporated herein by
reference in its entirety.
As explained herein, the rHSV helper function vector encodes the "AAV
helper function" sequences (i.e., rep and cap), which function in trans for
productive
AAV replication and encapsidation. Preferably, the rHSV helper function vector
supports efficient rAAV virion production without generating any detectable wt
AAV
virions (i.e., AAV virions containing functional rep and cap genes). An
example of
such a vector is rHSV-1 d27.1rc. The vector and methods of producing the same
are
described herein in the examples, as well as in Conway et al., Gene Ther.
(1999)
6:986-993; and U.S. Patent No. 7,091,029, incorporated herein by reference in
its
entirety.
The second rHSV vector is termed a rHSV expression vector and contains
ITRs from AAV with one or more genes of interest driven by one or more
promoters.
In some embodiments, the gene of interest is inserted between a pair of ITRs.
The
heterologous gene is typically functionally linked to a heterologous promoter
(constitutive, cell-specific, or inducible) capable of driving gene expression
in the
patient's target cells under appropriate conditions. Termination signals, such
as
polyadenylation sites, can also be included.
The nucleotide sequences of AAV ITR regions are known. See, e.g., Kotin,
R.M. (1994) Human Gene Therapy 5:793-801; Berns, K.I. "Parvoviridae and their
Replication" in Fundamental Virology, 2nd Edition, (B.N. Fields and D.M.
Knipe,
eds.) for the AAV-2 sequence. AAV ITRs used in the vectors of the invention
need
not have a wild-type nucleotide sequence, and may be altered, e.g., by the
insertion,
deletion or substitution of nucleotides. Additionally, AAV ITRs may be derived
from
any of several AAV serotypes, including without limitation, AAV-1, AAV-2, AAV-
3,
AAV-4, AAV-5, AAV-6, AAV-7 and AAV-8, caprine and bovine AAV (see, e.g.,
U.S. Publ. No. 20080292595. incorporated herein by reference in its entirety),
and
variants thereof. Furthermore, 5' and 3' ITRs which flank a selected
nucleotide
sequence in an expression vector need not necessarily be identical or derived
from the
same AAV serotype or isolate, so long as they function as intended, i.e., to
allow for
excision and rescue of the sequence of interest from a host cell genome or
vector, and
-22-
CA 02897444 2015-07-07
WO 2014/110053
PCT/US2014/010553
to allow integration of the DNA molecule into the recipient cell genome when
AAV
rep gene products are present in the cell.
AAV ITRs can be excised from the viral genome or from an AAV vector
containing the same and fused 5' and 3' of a selected nucleic acid construct
using
standard ligation techniques, such as those described in Sambrook et al.,
supra. For
example, ligations can be accomplished in 20 mM Tris-Cl pH 7.5, 10 mM MgC12,
10
mM DTT, 33 pg/m1 BSA, 10 mM-50 mM NaC1, and either 40 RM ATP, 0.01-0.02
(Weiss) units T4 DNA ligase at 0 C (for "sticky end" ligation) or 1 mM ATP,
0.3-0.6
(Weiss) units T4 DNA ligase at 14 C (for "blunt end" ligation). Intermolecular
"sticky end" ligations are usually performed at 30-100 pg/m1 total DNA
concentrations (5-100 nM total end concentration). AAV vectors which contain
ITRs
have been described in, e.g., U.S. Patent no. 5,139,941. In particular,
several AAV
vectors are described therein which are available from the American Type
Culture
Collection ("ATCC") under Accession Numbers 53222, 53223, 53224, 53225 and
53226.
The selected polynucleotide sequence is operably linked to control elements
that direct the transcription or expression thereof in a subject's cells. Such
control
elements can comprise control sequences normally associated with the selected
gene.
Alternatively, heterologous control sequences can be employed. Useful
heterologous
control sequences generally include those derived from sequences encoding
mammalian or viral genes. Examples include, but are not limited to, neuron-
specific
enolase promoter, a GFAP promoter, the SV40 early promoter, mouse mammary
tumor virus LTR promoter; adenovirus major late promoter (Ad MLP); a herpes
simplex virus (HSV) promoter, a cytomegalovirus (CMV) promoter such as the CMV
immediate early promoter region (CMVIE), a rous sarcoma virus (RSV) promoter,
synthetic promoters, hybrid promoters, and the like. In addition, sequences
derived
from nonviral genes, such as the murine metallothionein gene, will also find
use
herein. Such promoter sequences are commercially available from, e.g.,
Stratagene
(San Diego, CA), Invivogen (San Diego, CA) and others.
The gene of interest may be a gene likely to be of therapeutic value. Examples
of therapeutic genes include but are not limited to a-1 antitrypsin, Factor
VIII, Factor
IX, GAA, erythropoietin and PEDF. When it is desirable to select for or to
identify
successful transgene expression, the gene of interest may be a reporter gene.
Many
-23-
CA 02897444 2015-07-07
WO 2014/110053
PCT/US2014/010553
examples of genes used as reporters or for selection are known, and can be
used in the
invention. These include but are not limited to the genes encoding 13-
galactosidase,
neomycin, phosphoro-transferase, chloramphenicol acetyl transferase, thymidine
kinase, luciferase, beta-glucuronidase, aminoglycoside, phosphotransferase,
hygromycin B, xanthine-guanine phosphoribosyl, luciferase, DI-
IFR/methotrexate, and
green fluorescent protein (GFP).
The rHSV-1 expression virus can be produced in much the same manner as
described above, namely, by homologous recombination into the HSV-1 tk gene,
as
described in, e.g., Conway et al., Gene Ther. (1999) 6:986-993and U.S. Patent
No.
7,091,029, incorporated herein by reference in its entirety.
Once produced, the rHSV vectors, or any other virus of interest, is propagated
in culture in an appropriate cell line. For herpesviruses, such cell lines
include, but
are not limited to, Vero cells, 293 cells, HeLa cells, and the like, available
from the
American Type Culture Collection, Rockville, Md. If the HSV-1 d27.1 vector is
used, this virus will typically be cultured in the ICP27-complementing cell
line V27
(Rice et al., I Virol. (1990) 64:1704-1715).Any suitable medium for the virus
in
question, with or without serum, such as fetal bovine serum, can be used, such
as but
not limited to RPMI 1640 medium, Dulbecco's Modified Eagles Medium (DMEM),
F12 medium or a mixture of the latter (DF medium). If serum is present, the
culture
can include, for example 2% to 20% serum, more typically 5% to 15% serum, 7%
to
12% serum, or any number within these ranges, such as 5%, 6%, 7%, 8%, 9%, 10%,
11%, 12%, 13%, 14%, 15%, and the like. Moreover, if serum is used, it can be
present in the initial culture, and/or in subsequent fresh media added to the
cultures.
The amount of the iNOS inhibitor to be added in the method according to the
invention can be varied and is to a certain extent dependent on the particular
inhibitor
used, the medium used and the virus to be cultured. For example, when
herpesviruses
are cultured in Vero cells, the concentration of ATA in the initial culture,
if present,
will typically be 5 M to 500 M, preferably 10 M to 250 M, such as 20 M to
100 M, i.e., 30 M to 75 M, such as
30...35...40...45...50...55...60...65...70...75, etc.
or any integer within these stated ranges. Similarly, the concentration of
dexamethasone if present in the initial culture will typically be.1 M to 500
M,
preferably .5 M to 250 ?AM, such as 1 M to 100 M, i.e., 5 M to 75 !AM,
such as
1... 5... 15... 10... 20... 25...
30...35...40...45...50...55...60...65...70...75, etc. or any
-24-
CA 02897444 2015-07-07
WO 2014/110053
PCT/US2014/010553
integer within these stated ranges. If valproic acid is used, the initial
concentration
will be .1 mM to 500 mM, preferably .5 mM to 250 mM, such as 1 mM to 100 mM,
i.e., 5 mM to 75 mM, such as 1... 5... 15... 10... 20... 25... 30... 35...
40... 45... 50...
55... 60... 65... 70... 75, etc. or any integer within these stated ranges.
In certain embodiments, virus-infected cells are initially cultured in media
as
described above for .5 hours to 24 hours, such as .75 hours to 12 hours, 1
hour to 5
hours, 1 hour to 2 hours, or any number of hours or fractions thereof within
these
ranges. The iNOS inhibitor and/or serum may or may not be present in the
initial
culture. Fresh media is subsequently added and cultures incubated for 24 to
120
hours, such as 48 to 96 hours, 50 to 80 hours, 60 to 75 hours, 70 to 74 hours,
or any
number of hours or fractions thereof within these ranges. The iNOS inhibitor
and/or
serum may or may not be present in the subsequence culture, with the proviso
that the
iNOS inhibitor is present in either one or both of the initial culture and the
subsequent
culture.
In some embodiments, the iNOS inhibitor in the initial culture is present at a
higher concentration than in the subsequent culture. Thus, for example, if the
iNOS
inhibitor is ATA, it can be present in an amount of 30 to 75 1.1M in the
initial culture
and then 5 to 25 [IM in the subsequent culture. Alternatively, the inhibitor
can be
present only in the initial or the subsequent culture.
As shown in the examples below, one particularly preferred method using
ATA includes the presence of 50 tM ATA in the initial culture, with a
reduction in
the amount of ATA in the subsequent culture to 20 M. Additionally, in the
case of
ATA, it is preferable to include serum at the same time that ATA is present.
Thus, if
ATA is added to the initial culture, it is advantageous to add fetal bovine
serum (FBS)
to the media. Likewise, if ATA is added to the subsequent culture, the
addition of
FBS is necessary to obtain higher viral yields.
The viruses are then cultured to obtain a desirable titer of virus. For
example,
in the case of the HSV-1 d27-1 vectors described herein, ATA increases the d27-
1
yields in V27 cells supernatants 3- 5 times and the titers can be at least 1 x
108
PFU/ml or 4 x 108 DRP/ml. Similarly, ATA also increases the yields of wild
type (wt)
HSV-1 viruses strains McIntyre and KOS by 1 log, and the 293 or Vero titers
can be
up to 1 x 109 DRP/ml. The viruses are then harvested for further use.
-25-
CA 02897444 2015-07-07
WO 2014/110053
PCT/US2014/010553
For the purposes of the invention, suitable host cells for producing rAAV
virions include microorganisms, yeast cells, insect cells, and mammalian
cells, that
can be, or have been, used as recipients of a heterologous DNA molecule and
that are
capable of growth in, for example, suspension culture, flasks, plates, a
bioreactor, or
the like. The term includes the progeny of the original cell which has been
transfected. Thus, a "host cell" as used herein generally refers to a cell
which has
been transduced with an exogenous DNA sequence. If recombinant herpesviruses
are
produced in one type of cells for use in making rAAV virions, the harvested
vectors
are then transfected into another suitable host cell. 293 cells, originated
from a stable
human cell line, (readily available through, e.g., the American Type Culture
Collection under Accession Number ATCC CRL1573) are preferred host cells to
produce rAAV virions. Particularly, the human cell line 293 is a human
embryonic
kidney cell line that has been transformed with adenovirus type-5 DNA
fragments
(Graham et al. (1977) 1 Gen. Virol. 36:59), and expresses the adenoviral El a
and El b
genes (Aiello et al. (1979) Virology94:460). The 293 cell line is readily
transfected,
and provides a particularly convenient platform in which to produce rAAV
virions.
AAV helper functions are introduced into the host cell by transducing the host
cell with a rHSV helper function construct either prior to, or concurrently
with, using
the rHSV expression vector. rHSV helper constructs are thus used to provide at
least
transient expression of AAV rep and/or cap genes to complement missing AAV
functions that are necessary for productive AAV infection. AAV helper
constructs
lack AAV ITRs and can neither replicate nor package themselves.
Following recombinant AAV replication, rAAV virions can be purified from
the host cell using a variety of conventional purification methods, such as
column
chromatography, CsC1 gradients, and the like. For example, a plurality of
column
purification steps can be used, such as purification over an anion exchange
column, an
affinity column and/or a cation exchange column. See, for example,
International
Publication No. WO 02/12455.
The resulting rAAV virions containing the nucleotide sequence of interest can
then be used for gene delivery using techniques well known in the art and
described in
e.g., U.S. Patent Nos. 5,173,414 and 5,139,941; International Publication Nos.
WO
92/01070 (published 23 January 1992) and WO 93/03769 (published 4 March 1993);
Lebkowski et al., Molec. Cell. Biol. (1988) 8:3988-3996; Vincent et al.,
Vaccines 90
-26-
CA 02897444 2015-07-07
WO 2014/110053
PCT/US2014/010553
(1990) (Cold Spring Harbor Laboratory Press); Carter, B.J. Current Opinion in
Biotechnology (1992) 3:533-539; Muzyczka, N. Current Topics in Microbiol. and
Immunol. (1992) 158:97-129; Kotin, R.M. Human Gene Therapy (1994) 5:793-801;
Shelling and Smith, Gene Therapy (1994) 1:165-169; and Zhou et al., J Exp.
Med.
(1994) 179:1867-1875.
2. EXPERIMENTAL
Below are examples of specific embodiments for carrying out the present
invention. The examples are offered for illustrative purposes only, and are
not
intended to limit the scope of the present invention in any way.
Efforts have been made to ensure accuracy with respect to numbers used (e.g.,
amounts, temperatures, etc.), but some experimental error and deviation
should, of
course, be allowed for.
Materials and Methods
Cells
Vero-derived V27 cells (Rice et al., I Virol. (1989) 63:3399-3407) and human
embryonic kidney cells (HEK)-derived 293 cells (Graham et al., I Gen. Virol.
(1977)
36:59-74) were obtained from the Applied Genetic Technologies Corporation
(AGTC,
Alachua, FL), Vero and HeLa cells were purchased from American Type Culture
Collection (ATCC, Manassas, VA). All cells were maintained in Dulbecco's
modified Eagle's medium (DMEM; HyClone, South Logan, UT) containing 10% fetal
bovine serum (FBS; HyClone) and either Geneticin (50mg/m1; Invitrogen) for V27
cells or 1% penicillin/streptomycin (Cellgro Mediatech, Manassas, VA) for the
other
cells.
HSV-1 Production
The wtHSV-1 KOS strain and the ICP27-deficient derivatives of the wtHSV-1
KOS strain: vectors d27-1 (Rice and Knipe, I Virol. (1990) 64:1704-1715), rHSV-
rep2/cap2 and rHSV-EGFP (Kang et al., Gene Ther. (2009) 16:229-239) and their
producer ICP27-complementing V27 cell line were obtained from AGTC (Alachua,
FL). The wtHSV-1 MacIntyre strain, purchased from Advanced Biotechnologies
Inc.
(ABI, Columbia MD) and wtHSV-1 KOS strain were propagated in Vero, 293 or
-27-
CA 02897444 2015-07-07
WO 2014/110053
PCT/US2014/010553
HeLa cell lines. Infectious vector particles were harvested 72 hr
postinfection by
recovering culture supernatant. The titers of HSV-1 stocks in DNase resistant
particles/ml (DRP/ml) were determined by Taqman assay. Viral genomes within
crude culture medium were quantified via treatment in the presence of DNase
1(50
U/ml final; Promega) at 37 C for 60 min, followed by proteinase K (Invitrogen)
digestion (1 U/ml) at 50 C for 60 min, and then denatured at 95 C for 30 min.
Linearized plasmid pZero 195 UL36(obtained from AGTC, Inc., Alachua, FL) was
used to generate standard curves. The primer¨probe set was specific for the
vector
genome UL36 sequence (HSV-UL36 F: 5'- GTTGGTTATGGGGGAGTGTGG (SEQ
ID NO:1); HSV-UL36 R: 5'-TCCTTGTCTGGGGTGTCTTCG (SEQ ID NO:2);
HSV-UL36 Probe: 5'- 6FAM ¨ CGACGAAGACTCCGACGCCACCTC-TAMRA
(SEQ ID NO:3). Amplification of the PCR product was achieved with the
following
cycling parameters: lcycle at 50 C for 2 min, 1 cycle at 95 C for 10 min; 40
cycles
of95 C for 15 sec, and 60 C for 60 sec.
ATA Experiments
ATA (Sigma -A1895 Aurintricarboxylic acid practical grade,>85% (titration),
powder) stock solution was generated as 500 1.1M concentration in 100 mM
sodium
bicarbonate water solution. ATA stock solution was further diluted in DMEM+/-
10%
fetal bovine serum (FBS, Hyclone, Waltham, MA) into concentration ranges of 12-
60
ATA (8.5-21 gATA /m1). The HSV-1 infection at multiplicity of infection of
0.15 (M01=0.15) (typically 6x105 cells in a 6-well plate)was performed in 40%
(2/5
vol) of the total final media volume for 1-2 hrs and the remaining media (60%
or 3/5
of the total final volume) was added during the dilution step. The cells were
then
incubated 72 hours and supernatant harvested to perform forming units per
milliliter
(PFU/m1)and DRP/ml titer assays.
Dexamethasone(Dex) Experiments
Dexamethasone (Sigma ¨D4902) was dissolved to 2 mg/ml in absolute
alcohol. This was diluted with DMEM to achieve a 1M concentration and stored
at -
20 C.
-28-
CA 02897444 2015-07-07
WO 2014/110053
PCT/US2014/010553
V27 cells were seeded into six well plates the day prior to infection at 6x105
cells/well. Dexamethasone was added to achieve a concentration of 1 tM into
the
seeding media. This was mixed well and added to the wells.
Media was aspirated and infectious HSV-1 d27-1 stock was added at MOI
0.15 (= cell seed density x 0.15/ pfu titer of HSV stock) per lml of DMEM (no
additives). 1 ml of infectious inoculum was added per well. This was incubated
for
1-2 hours at 37 C, 5% CO2 incubator, after which time 1.5 ml of DMEM-10% FBS
was added. The cultures were returned to the incubator for 70-74 hours.
Free media was harvested, vortexed, centrifuged at 1,100 x g for 10 minutes at
4 C. Supernatant was transferred to a new dispensing tube, vortexed, aliquoted
and
stocks were frozen at -80 C.
Valproic Acid (VA) Experiments
Valproic acid (Sigma ¨P4543) was dissolved to 1 M concentration in water.
V27 cells were seeded into six well plates the day prior to infection at 6x105
cells/well. 1 M valproic acid was spiked into 1 ml DMEM-10% FBS to achieve a
concentration of 5 1.iM . This was vortexed well and added to the wells.
Plates were
incubated for six hours, aspirated and infectious HSV-1 d27-1 stock added at
MOT
0.15 (= cell seed density x 0.15/ pfu titer of HSV stock) per lml of DMEM (no
additives).
lml of infectious inoculum was added per well and incubated for 1-2 hours at
37 C, 5% CO2 incubator after which time 1.5 ml of DMEM-10% FBS was added.
The plates were returned to the incubator for 70-74 hours. Free media was
harvested,
vortexed, and centrifuged at 1,100 x g for 10 minutes at 4 C. Supernatant was
transferred to a new dispensing tube, vortexed, and aliquoted. Stocks were
frozen at
-80 C.
rAAV Production
293 cells (2.5 x106) were simultaneously co-infected with both rHSV-rep2/cap2
and rHSV-EGFP vectors as described by Kang et al., Gene Ther (2009) 16:229-
239. At
2-4 hr post infection, infectious medium was exchanged with DMEM +10% FBS
equivalent to double the preinfection culture volume. At the time of harvest,
the cell
pellet was frozen at-80 C. DRP titers were quantified by real-time polymerase
chain
-29-
CA 02897444 2015-07-07
WO 2014/110053
PCT/US2014/010553
reaction (qPCR) in a96-well block thermocycler (Applied Biosystems; 7500 Real
Time PCR system). Crude samples were subjected to three cycles of freezing and
thawing, then incubated in the presence of Benzonase (250U/m1), 2mM MgC12, 1%
final concentration protein grade Tween 80 (Calbiochem) and incubated at 37 C
for60
min, followed by 0.25% Trypsin (Gibco) digestion at 50 C for 60 min. Finally,
treatment with DNase 1(50 U/ml; Promega) at 37 C for 30 min, and then
denatured at
95 C for 20 min. Linearized plasmidpDC67/+SV40 was used to generate standard
curves. The primer¨probe set was specific for the simian virus 40 (SV40)
poly(A)
sequence: rAAV-F: 5'- AGCAATAGCATCACAAATTTCACAA-3' (SEQ ID
NO:4);rAAV-R: 5'-GCAGACATGATAAGATACATTGATGAGTT-3' (SEQ ID
NO:5) ;rAAV-Probe: 5' 6-FAM-
AGCATTITTTTCACTGCATTCTAGTTGTGGT11TGTC-TAMRA-3' (SEQ ID
NO:6). Amplification of the PCR product was achieved with the following
cycling
parameters: lcycle at 50 C for 2 min, 1 cycle at 95 C for 10 min; 40 cycles
of95 C
for 15 sec, and 60 C for 60 sec.
Human Genome Array
Confluent 293 cells (2.4x106 cells in a 75 cm2 flask) were cultured in DMEM
+ 10% FCS for approximately 20 hrs and were then infected with one plaque
forming
unit per cell (PFU/cell) of HSV-1 MacIntyre Strain for 90 min. ATA at a
concentration 20 IAM (final) was added 90 min post-infection. The infected
cells were
harvested at 24 h after infection. Total RNA of sufficient quality and
quantity was
isolated from suspension using RNeasy Plus Mini Kit (QIAGEN, Valencia, CA)
according to the manufacturer's instructions. Whole genome expression
profiling was
performed on Affymetrix Human U133 Plus 2.0 Array by the Asuragen, Inc.3 [tg
total
RNA was provided as input material.
Overall, RNA quality assessed on the bioanalyzer had RIN values of >9. Array
hybridization and scaling factors were within passing quality control range.
After
scanning, raw expression CEL files were processed with Affymetrix Expression
Console vs.1.1.2 (affymetrix.com). Each CEL file was processed with Robust
Multichip Analysis (RMA) and a summarized table was exported as a text file.
All
downstream genomics and statistical analyses were done with JMP Genomics
(version 5) (jmp.com/software/genomics). First, a filtering step was applied
to filter-
-30-
CA 02897444 2015-07-07
WO 2014/110053
PCT/US2014/010553
out low expression, specifically, those values below 6 in log2 mode in at
least 2 out of
8 samples. Out of 54,675 total Affy U133 Plus2 probes, 41,569 (76%) probes
remained after the cutoff. Two positive control samples were also seen, human
brain
and pooled human universal reference RNA, respectively, that hybridized well.
For
future analysis, these two samples were excluded.
Principle Component Analysis revealed two distinct populations, samples
treated with and without HSV. The first principle component separation (91.7%)
is
therefore explained by the effect of HSV versus Vehicle. Data was median-
normalized across each probe to have a median signal of O. ANOVA was performed
to find significant differential transcripts between HSV versus Vehicle, ATA
versus
Vehicle, HSV+AVA versus Vehicle, and HSV+ATA versus HSV alone. Multiple
testing corrections were not included, and significant genes were considered
less that
p-value of 0.01.
A self-organized map was used to examine patterns of expression among
Vehicle, HSV I, and HSVI+ATA. It was desired to find specific transcripts that
were
either up-regulated or down-regulated by the ATA treatment. A distinct cluster
of
genes that showed some stimulation in the presence of HSV was found, and ATA
correction brought these genes back to vehicle baseline. Similarly, a cluster
of genes
that were repressed by HSV compared to the vehicle was also found, and
subsequently activated by treatment with ATA. These were called Clusters A and
B,
respectively (see, Tables 1 and 2). Analysis was followed-up to interrogate
the
biological functions of these clusters using GeneGO software (genego.com).
RT2 ProfilerTM PCR Array (SABiosciences- QIAGEN)
6x10e5 293 cells (from AGTC) were infected with wtHSV-1 McIntyre strain at
MOI I in the presence of DMEM & 10% FBS with or without 50uM ATA and 1-2
hours and diluted to 40% with DMEM & 10% PBS (final ATA concentration of
20uM). Triplicate total RNA samples were harvested 24 hrs later using Qiagen
RNeasy mini kit and DNase treated on the column and eluted. Eluate RNA
triplicate
samples were combined and photospectrometer O.D. readings were performed on
the
eluate at 260 and 280nm to determine concentration. Sample RNA was converted
into
template cDNA using SABiosciences RT2 first strand kit. The cDNA was then used
in the Human JAK / STAT Signaling Pathway PCR Array (PAHS-039A).
-31-
CA 02897444 2015-07-07
WO 2014/110053
PCT/US2014/010553
Example 1
Inhibition of HSV-Induced iNOS Levels in V27 Cells using ATA
V27 cells in Dulbecco's Modified Eagles Medium (DMEM) (Hyclone, Waltham,
MA) were infected with the HSV-1 d27.1 vector at an MOI of 1 and treated with
30
jiM ATA (Sigma, St. Louis, MO), with or without 10% fetal bovine serum (FBS).
Control experiments without ATA were also performed.V27 cell lysates were
obtained 24 hours post infection (h.p.i.) and Western blots were run on the
lysates and
iNOS protein was detected by using purified rabbit anti-iNOS/NOS Type II pAb
(BD
Biosciences, Cat# 610332). Results are shown in Figure 1.
As shown, HSV infection induced iNOS expression in those cultures that did
not include ATA (lanes 4 and 5). iNOS expression was inhibited in the presence
of
30 M ATA (lanes 2 and 3). The presence or absence of 10% FBS did not have an
effect on iNOS expression.
Example 2
Optimization of ATA-HSV Protocol
In order to test whether ATA could increase the rHSV-1 d27-1 (d27-1) vector
yield in V27 cells, ATA was applied to the media during the infection (Step 1)
or
dilution steps (Step 2) (Figure 2A). The d27-1 infection at MOI=0.15 was
performed
in 2/5 of the final media volume and the remaining 3/5 of the media was added
during
dilution step.
ATA treatment delayed HSV-1 plaque formation or cell lysis inV27 cell
monolayers. Cytopathic effect (CPE) at the time of harvest, 72 hours post-
infection,
(hpi) was between 20-60% as compared to 100% CPE in the absence of ATA.
Treatment with ATA during the HSV-1 infection step (ATA at Step 1) showed
increased d27-1 titers in V27 cells supernatants harvested at 72 hpi (Figure
4B). The
optimal ATA concentration when added during the infection step (ATA I) was 50
jiM
and this was further diluted to the final concentration (f.c.) of 20 1.1M ATA
during the
dilution step by adding the remaining 3/5 vol of the media. In this case, ATA
increased d27-1 titers in supernatant at the time of harvest (72 h.p.i.) about
10 times:
from 4.0 0.3 x107DRP/m1 or 1.4 0.2x107PFU/m1 to 3.7 0.2 x108DRP/m1 or 1.2
0.3
x108PFU/m1 (Figure 4B).
-32-
CA 02897444 2015-07-07
WO 2014/110053
PCT/US2014/010553
In order to determine which concentrations and conditions for ATA addition
have impact on HSV yields, the following experiments were conducted. ATA at
varying concentrations was added to V27 cultures infected with the HSV-1 d27-1
vectors in either six-well plates (Figure 2B) or T150 flasks (Figure 2C) in
two steps as
follows. In Step 1 of the protocol, V27 cells were infected with 0.15 MOI of
the
rHSV vector in 2/5 of the final volume of DMEM with 10% FBS and 0-60 1.tM ATA
concentrations. Cells were cultured for 1-2 hours at 37 C to complete Step 1.
In Step
2, the concentration of ATA was reduced to a range between 12-24 [tM by the
addition of 3/5 of final media volume. Cells were cultured for 70-74 hours at
37 C
and the supernatant harvested. Viral titers were expressed as Dnase Resistant
Particles (DRP/ml) or Plaque Forming Units (pfu/ml) per ml and were determined
as
described above.
Results are shown in both Figures 2B and 2C and optimal ATA concentrations
are bolded. As can be seen, in both six-well plates (Figure 2B) and T150
flasks
(Figure 2C), cultures with ATA added in either of Step 1 or Step 2 had
significantly
higher HSV titers than those without ATA. Moreover, the highest titers were
seen at
ATA concentrations of 50 [tM in Step 1, reduced to 20 [IM in Step 2 (Figure
2B),
although all concentrations of ATA produced higher viral titers than those
cultures
that lacked ATA.
Additional experiments were conducted to determine optimal conditions and
the effect of the presence or absence of FBS on HSV titer. The serum presence,
specifically, 10% fetal bovine serum (FBS), in ATA-containing media was the
most
important parameter for the ATA-induced HSV-1 titer yield. A supplementation
of
ATA into serum-free media during the dilution step (ATA at Step 2) caused
reduction
of virus titer, where the "DRP" titer was reduced below control level and
PFU/ml titer
was below detection (Figure 3). An even more dramatic effect in serum-free
media
was seen when ATA, starting at 3 [1.1\4 concentration, was supplemented during
the
infection Step 1 and both DRP/ml and PFU/ml titers were below the detection
limit.
In this experiment, V27 cells were seeded into six well plates the day prior
to
infection at 6x105 cells/well. HSV 2x infection solution was prepared as
follows:
HSV-1 d27.1 stock was added to DMEM (no FBS) at 2x titer that the cells would
be
infected at final MOI 0.15. Several 2xATA solution combinations were prepared
-33-
CA 02897444 2015-07-07
WO 2014/110053
PCT/US2014/010553
containing either 100 H.M or 40 tiM ATA in DMEM and without FBS or with 20%
FBS.
HSV 2x infection solution was mixed equal volumes of either DMEM -/+
20%FBS or desired 2xATA solution -/+ 20% FBS, vortexed, and lml of infectious
inoculum per well was added in Step 1. If wells contained ATA in Step 1, the
concentration was 50 M and all wells were incubated for 1-2 hrs. In Step2,
additional 1.5 ml of DMEM combinations -1+40 [tM ATA and -/+20% FBS were
added. If wells contained ATA whether in Step 1 or Step 2, the final ATA
concentration was 20 M.The plates were returned to the incubator for 70-74
hours
after which time free media was harvested, vortexed, and centrifuged at 1,100
x g for
10 minutes at 4 C. Supernatants were transferred to a new dispensing tube,
vortexed,
aliquoted and stocks were frozen at -80 C.
Example 3
Importance of Serum Presence in ATA-HSV Protocol
Additional experiments were conducted to determine optimal conditions and
the effect of the presence or absence of FBS on HSV titer. The serum presence,
specifically, 10% fetal bovine serum (FBS), in ATA-containing media was the
most
important parameter for the ATA-induced HSV-1 titer yield. A supplementation
of
ATA into serum-free media during the dilution step (ATA at Step 2) caused
reduction
of virus titer, where the "DRP" titer was reduced below control level and
PFU/ml titer
was below detection (Figure 3). An even more dramatic effect in serum-free
media
was seen when ATA, starting at 3 [tM concentration, was supplemented during
the
infection Step 1 (data not shown) and both DRP/ml and PFU/ml titers were below
the
detection limit.
In this experiment, V27 cells were seeded into six well plates the day prior
to
infection at 6x105 cells/well. HSV 2x infection solution was prepared as
follows:
HSV-1 d27.1 stock was added to DMEM (no FBS) at 2x titer that the cells would
be
infected at final MOI 0.15. Several 2x ATA solution combinations were prepared
containing either 100 1.1M or 40 [tM ATA in DMEM and without FBS or with 20%
FBS. HSV 2x infection solution was mixed equal volumes of either DMEM -/+
20%FBS or desired 2xATA solution -/+ 20% FBS,vortexed, and lml of infectious
inoculum per well was added in Step 1. If wells contained ATA in Step 1, the
-34-
CA 02897444 2015-07-07
WO 2014/110053
PCT/US2014/010553
concentration was 50tiM and all wells were incubated for 1-2 hrs. In Step 2,
additional 1.5 ml of DMEM combinations -/+ 40 uM ATA and -/+20% FBS were
added. If wells contained ATA whether in Step 1 or Step 2 , the final ATA
concentration was 20 M. The plates were returned to the incubator for 70-74
hours
after which time free media was harvested, vortexed, and centrifuged at 1,100
x g for
minutes at 4 C. Supernatants were transferred to a new dispensing tube,
vortexed,
aliquoted and stocks were frozen at -80 C.
Example 4
10 Effect of ATA on Wild Type HSV Titers in Culture
Figure 4A shows supernatant titers of both wtHSV-1 strains, KOS and
McIntyre in cell lines permissive for wtHSV-1 propagation: 293 cells, HeLa and
Vero
cells. wtHSV-1 strains KOS and McIntyre were propagated in 293, HeLa and Vero
cells using the ATA-HSV Protocol where 50 M ATA was added at Step 1 and the
final
concentration after Step 2 was diluted to 20 1.i.M ATA. Supernatants
containing virus
were harvested after three days as described above. ATA increased the yield of
both
virus types in Vero cells. wtHSV-1 McIntyre strain reached the highest titers
after
ATA induction in 293 cells, however, ATA appeared to inhibit HSV-1 KOS growth
in 293 cells. Finally, ATA also appeared to inhibit both types of HSV-1
viruses in
HeLa cells. Two-way ANOVA; Bonferroni test; - ATA vs. + ATA: ***: p<0.001, ns:
p>0.05; n=4 independent experiments.
For statistical calculations, a larger study with a set of ten independent
experiments (n=10) was conducted in 6-well plates with or without ATA added
during the infection step (Step 1) comparing replication-deficient d27-GFP and
also
wtHSV-1 McIntyre strain in order to investigate, whether ATA could increase
the
titer in the wtHSV-1 strain as well (Figure 4B). ATA was added at 50mM to
confluent cell monolayers, V27 cells for d27-1 or 293 cells for wtHSV-1
McIntyre,
during the infection step ( Step 1) and the cells were infected with vectors
at
MOI=0.15 while ATA was diluted 1 hr later to a final 20 mM concentration.
After
ATA addition, d27-1 titer significantly increased 6.1 times from 5.4
x107DRP/m1 or
1.1 x108DRP/m1 (**P<0.01) and wtHSV-1 McIntyre significantly increased 9.1
times
from 3.3 x108DRP/m1 or 1.0 x109DRP/m1(***P<0.001) as analyzed by 2-way
ANOVA and Bonferroni test (Figure 4B).
-35-
CA 02897444 2015-07-07
WO 2014/110053
PCT/US2014/010553
1
Example 5
Effect of ATA in HSV Stocks on the Production or rAAV Virions
In order to determine whether the presence of ATA during HSV production
impacted the yield of rAAV virions produced using HSV vectors, the following
experiment was performed showing rAAV titers affected by ATA residue present
from
rHSV-1 stocks produced in 293 cells (Figure 5A). The rAAV-GFP vector was
produced by co-infection ofrHSV-rep2/cap2 and rHSV-EGFP vectors in 293 cells
60mm plates using ATA-containing rHSV-lstocks prepared under different
concentrations ATA concentrations (12 M or 20 M f.c.) (see Material and
Methods).
rAAV DRP/ml titer was slightly increased by 1.3 times when using the rHSV-
rep2/cap2 stock that was prepared with 20 [IM ATA added during infection (ATA
Step 1) versus "No ATA" Control (*p<0.05), where the ATA concentration during
rAAV production was approximately 3 IIM. No significant rAAV titer increase
was
detected when using the rHSV-rep2/cap2 stock that was prepared with 12 M ATA
(Figure 5A). One-way ANOVA; Tukey's-test:*p<0.05; 20 M ATA vs. No ATA;
n=4 independent experiments.
In another experiment, ATA was shown to increase rAAV titer when 10 I.LM
ATA was spiked directly into 293 cells media during 2 hrs of rHSV-rep2/cap2
and rHSV-
EGFP co-infection step. This effect was not observed when the ATA
concentrations
were higher then 20 [IM (Figure 5B).
Example 6
ATA Mechanism of Action
In order to illuminate the ATA mechanism of action by human genome array
and the fact that Vero and V27 are monkey-derived cell lines, wtHSV-1
propagation
was tested in several human cell lines (Figures 4A-4B). A propagation of two
wild
type HSV-1 (wtHSV-1) strains, KOS and McIntyre, were compared in three cell
lines:
human embryonic kidney 293 (293 cells),human cervical cancer HeLa cells and
African green monkey kidney epithelial Vero cells. The experiments were
carried out
in 10%FBS-containing media following the ATA I protocol scheme, where 50 [tM
ATA was supplemented during the infection step and further diluted to 20 M ATA
concentration (see Material and Methods). In human-derived 293 cells, only the
-36-
CA 02897444 2015-07-07
WO 2014/110053
PCT/US2014/010553
wtHSV-1 McIntyre virus titer increased significantly by ATA, from
1.4x108DRP/m1
to 1.2 x109DRP/m1(***p<0.001). In Vero cells, ATA significantly increased
titers
only in wtHSV-1 KOS strain from 1.7x108DRP/m1 up to 9.1x108DRP/m1
(***p<0.001; both statistics: Two-way ANOVA, Bonferroni test; n=4).
Surprisingly,
in HeLa cells, ATA seemed to inhibit propagation of both KOS and McIntyre HSV-
1
strains.
To identify cell response gene signatures to wtHSV-1 McIntyre infection,
transcriptional profiling was done using Affymetrix Human U133 Plus 2.0 Array
with
293 cells that were either mock-treated, ATA-treated (ATA), wtHSV-1 McIntyre-
infected (HSV) or ATA-treated and wtHSV-1 McIntyre-infected (HSV&ATA) for 24
h. Gene expression changes induced by infection or ATA treatment were
identified by
referencing the gene expression level for each probe to that corresponding in
the
uninfected cells sample. HSV-1 infection alone had strong impact on the gene
expression profile of 293 cells when compared to untreated cells gene profile.
First, a filtering step was applied to filter out low expression and out of
54,675
total Affy U133 Plus2 probes, 41,569 (76%) probes remained after the cutoff.
Principle Component Analysis revealed two distinct populations, samples
treated with
and without HSV. ANOVA was performed to find significant differential
transcripts
between HSV versus Vehicle, ATA versus Vehicle, HSV+AVA versus Vehicle, and
HSV+ATA versus HSV alone. Significant genes were considered less than a p-
value
of 0.01. A self-organized map was used to examine patterns of expression among
Vehicle, HSV1, and HSV1+ATA. A distinct cluster of genes was found, Cluster A
and B (Tables 1 and 2), that showed changes in transcriptional profiles caused
by
HSV-1 and their correction by ATA that brought these genes back to vehicle
baseline.
The biological functions of these clusters were analyzed in GeneGo. Cluster
A (Table 2) represented 58 probes that showed up-regulation in HSV-1 and
suppression after the addition of ATA. These genes were primarily involved in
inflammatory IgE and IFN signaling, and general immune response. Cluster B
(Table 1) represented 152 probes that showed down-regulation by HSV-1 and
their
subsequent ATA up-regulation by bringing them back to vehicle baseline. Genes
in
this cluster were primarily involved in cell cycle Gl/S, signal transduction
in PTEN,
and WNT development. For example, ATA in the presence of HSV-1 up-regulated
CDC25A, CDKN1A, CDKN1C, CCNK, CNNM2 genes from cell cycle progression
-37-
CA 02897444 2015-07-07
WO 2014/110053
PCT/US2014/010553
pathways and genes from Ras/Raf/MEK pathway, such as FOXCl, FOXD3, FOX03
(See, Table 1).
Tables 3A and 3B show nNOS, iNOS and eNOS expression reduction in HSV
ATA samples as analyzed by Affymetrix Gen Array and iNOS expression reduction
in HSV + ATA samples as analyzed by Qiagene SAB Jak-Stat RT¨PCR Microarray
Example 7
Effect of Dexamethasone on HSV Yields
In order to determine whether the iNOS inhibitor dexamethasone also
increased rHSV yields in culture, the following experiment was conducted
(Figure 6).
shows the effect of dexamethasone (Dex) on d27-1/GFP HSV-1 viral titer. The
final
titers d27-1/GFP HSV-1 were, in general, slightly elevated after dex
pretreatments or
treatments as compared to untreated control.
V27 cells were seeded into six well plates the day prior to infection at 6x105
cells/well and the next day, different concentrations of dexamethasone (dex)
were
added to the wells either before HSV-1 infection (pretreat) or during the
infection
(treat) in 2/5 vol of DMEM-10% FBS media. After 1-2 hours of incubation at 37
C,
3/5 vol. of DMEM-10% FBS was added. The cultures were returned to the
incubator
and supernatant was harvested after 70-74 hours. The data are shown as Mean
value
of titers + S.D. in pfu/ml (n=2).
Example 8
Effect of Valproic Acid on HSV Yields
In order to determine whether the iNOS inhibitor valproic acid also increased
rHSV yields in culture, the following experiment was conducted. Figure 7 shows
the
effect of pretreatment by valproic acid (VA) on d27-1/GFP HSV-1 viral titer.
VA at
concentration 5mM slightly elevated the titer of d27-1/GFP HSV-1, however the
concentrations bellow and above of 5 mM appear to have an inhibitory effect on
d27-
1/GFP HSV-1 titer, as compared to untreated control.
V27 cells were seeded into six well plates the day prior to infection at 6x105
cells/well and the next day, different concentrations of VA were added to
wells. Plates
were incubated for 6 hrs, aspirated and 2/5 vol of media containing infectious
HSV-1
d27-1 stock was added and incubated for 1-2 hours at 37 C, 5 after which time
3/5 vol
-38-
CA 02897444 2015-07-07
WO 2014/110053
PCT/US2014/010553
of DMEM 10% FBS media was added. The cultures were returned to the incubator
and supernatant was harvested after 70-74 hours.
As shown in the foregoing examples, ATA in micromolar concentrations
increases HSV-1 vector yield. This finding is important for both large-scale
HSV
production, as well as rHSV and rAAV vector production. Moreover and
surprisingly, the presence of ATA in rHSV-1 stocks did not negatively
influence
rAAV yield. This result is surprising as ATA in millimolar amounts and higher
concentrations is known to be an antiviral agent (Cushman et al., J Med Chem.
(1991) 34:329-337; Zhang et al., Antiviral Res. (1999) 43:23-35; Yap et al.,
Computational Biol. and Chem. (2005) 29:212-219; De Clercq, Advents, Advances,
and Adventures Med Res. Rev. (2011) 31:118-160). In serum-free media the
inventors have also observed a possible antiviral effect of ATA at micromolar
concentrations, but not in the presence of serum (10% FBS).
Also as shown herein, ATA treatment delayed HSV-1 plaque formation and cell
lysis in V27 cells monolayers and cytopathic effect (CPE), which evidences
antiapoptotic properties. The mechanism of action of ATA in the increase of
HSV-1
yield appears to involve changes in factors required for HSV-1 production and
reduction of cellular innate antiviral immune response responsible for a viral
clearance. From the Human Genome Array analysis above, it was discovered that
HSV-1 infection alone has strong impact on the gene expression profile of 293
cells
and the effect of ATA was mostly observed in cells treated with both HSV-1 and
ATA. Genes involved in cell cycle Gl/S, signal transduction in PTEN, and WNT
development were significantly down-regulated by HSV-1 and up-regulated after
addition of ATA.
Genes primarily involved in inflammatory IgE and IFN signaling, and general
immune response were up-regulated by HSV-1 and suppressed after the addition
of
ATA. In the presence of HSV-1, ATA up-regulated CDC25A, CDKN1A, CDKN1C,
CCNK, CNNM2 genes from the cell cycle progression pathways and genes from the
Ras/Raf/MEK pathway, including FOXCl, FOXD3, FOX03.
The finding that ATA can increase HSV-1 yield are important because of the
need of higher yields of HSV-1 vectors for large-scale production for gene
therapy
and other applications.
-39-
CA 02897444 2015-07-07
WO 2014/110053
PCT/US2014/010553
Thus, methods for increasing viral yields using iNOS inhibitors are described.
Although preferred embodiments of the subject invention have been described in
some detail, it is understood that obvious variations can be made without
departing
from the spirit and the scope of the invention as defined herein.
-40-
CA 02897444 2015-07-07
WO 2014/110053 PCT/US2014/010553
Table 1. Cluster B gene list: Genes suppressed by HSV and up-
regulated by HSV+ATA
Probe_Set_ Gene Symbol Gene_Title Estimate of p-Value
for
ID HSV+ATA vs HSV Estimate of
HSV+ATA vs HSV
230304_at --- --- 2.1691 0.0001
225806_at JUB jub, ajuba homolog 2.126171 0.0004
(Xenopus laevis)
202935_s_a 50X9 SRY (sex determining 1.855105 0.000046
t region Y)-box 9
204790_at SMAD7 SMAD family member 7 1.797951 0.0029
214633_at SOX3 SRY (sex determining 1.797254 0.000007
region Y)-box 3
210512_s_a VEGFA vascular endothelial 1.754719 0.000021
t growth factor A
216652_s_a DR1 down-regulator of 1.74529 0.0036
t transcription 1, TBP-
binding (negative
cofactor 2)
205932_s_a MSX1 msh homeobox 1 1.726634 6.90E-06
t
209348_s_a MAF v-maf 1.685705 0.0073
t musculoaponeurotic
fibrosarcoma oncogene
homolog (avian)
217028_at CXCR4 chemokine (C-X-C 1.652962 0.0093
motif) receptor 4
218251_at MID1IP1 MIDI interacting 1.642017 0.0064
protein 1 (gastrulation
specific G12 homolog
(zebrafish))
1553764_a JUB jub, ajuba homolog 1.623019 0.0017
_at (Xenopus laevis)
214446_at ELL2 elongation factor, RNA 1.602283 0.0001
polymerase II, 2
227718_at PURB purine-rich element 1.59314 0.0019
binding protein B
-41-
CA 02897444 2015-07-07
WO 2014/110053
PCT/US2014/010553
219624_at BAG4 BCL2-associated 1.578527 0.0007
athanogene 4
225642_at KTI12 KTI12 homolog, 1.566082 0.0002
chromatin associated
(S. cerevisiae)
203705_s_a FZD7 frizzled homolog 7 1.54382 0.0002
(Drosophila)
222696_at AXIN2 axin 2 1.526076 0.0066
202007_at NID1 nidogen 1 1.521713 0.0029
226858_at CSNK1E casein kinase 1, epsilon 1.51752 0.0002
57739_at DND1 dead end homolog 1 1.515518 0.0005
(zebrafish)
1558290_a PVT1 Pvt1 oncogene (non- 1.515288 0.0016
_at protein coding)
215694_at SPATA5L1 spermatogenesis 1.51283 0.0012
associated 5-like 1
206302_s_a NUDT4 /1/ nudix (nucleoside 1.49443 0.0073
NUDT4P1 diphosphate linked
moiety X)-type motif 4
/// nudix (nucleoside
diphosphate linked
moiety X)-type motif 4
pseudogene 1
218486_at KLF11 Kruppel-like factor 11 1.493386 0.0006
201695_s_a NP nucleoside 1.492386 0.0004
phosphorylase
203002_at AMOTL2 angiomotin like 2 1.489062 0.0093
227195_at ZNF503 zinc finger protein 503 1.478008 0.0094
238012_at DPP7 Dipeptidyl-peptidase 7 1.471194 0.0003
209905_at HOXA9 homeobox A9 1.46661 0.0003
209188_x_a DR1 down-regulator of 1.4541 0.0001
transcription 1, TBP-
binding (negative
cofactor 2)
221168_at PRDM13 PR domain containing 1.448075 0.0043
13
213338_at TMEM158 transmembrane 1.436626 0.0001
-42-
CA 02897444 2015-07-07
WO 2014/110053
PCT/US2014/010553
protein 158
209098_s_a JAG1 jagged 1 (Alagille 1.433177 0.0001
syndrome)
206300_s_a PTHLH parathyroid hormone- 1.430301 0.0004
like hormone
220018_at CBLL1 Cas-Br-M (murine) 1.427214 0.00003
ecotropic retroviral
transforming
sequence-like 1
226284_at ZBTB2 zinc finger and BTB 1.421748 6.50E-06
domain containing 2
213348_at CDKN1C cyclin-dependent 1.413731 0.0001
kinase inhibitor 1C
(p57, Kip2)
209565_at RNF113A ring finger protein 1.413412 7.80E-06
113A
239696_at 1.413287 0.0006
212696_s_a RNF4 ring finger protein 4 1.408882 0.0034
214651_s_a HOXA9 homeobox A9 1.404355 0.000042
217741_s_a ZFAND5 zinc finger, AN1-type 1.401465 0.0003
domain 5
229309_at ADRB1 adrenergic, beta-1-, 1.398788 0.0008
receptor
228953_at WHAMM WAS protein homolog 1.392654 0.0013
associated with actin,
golgi membranes and
microtubules
1554522_at CNNM2 cyclin M2 1.389108 0.0049
204913_s_a SOX11 SRY (sex determining 1.385923 0.0004
region Y)-box 11
231901_at C19orf52 chromosome 19 open 1.378798 0.0034
reading frame 52
224314_s_a EGLN1 egl nine homolog 1 (C. 1.375757 0.0001
elegans)
209099_x_a JAG1 jagged 1 (Alagille 1.374203 0.0029
-43-
CA 02897444 2015-07-07
WO 2014/110053
PCT/US2014/010553
syndrome)
205555_s_a MSX2 msh homeobox 2 1.368114 0.00003
216035_x_a TCF7L2 transcription factor 7- 1.368112 0.0003
like 2 (T-cell specific,
HMG-box)
225824_at CCNK cyclin K 1.363977 0.0076
209201_x_a CXCR4 chemokine (C-X-C 1.360311 0.0001
motif) receptor 4
235147_at FU32063 Hypothetical 1.357503 0.0008
LOC150538
204527_at MY05A myosin VA (heavy chain 1.356721 0.0017
12, myoxin)
242963_at SGMS2 sphingomyelin 1.356199 0.0008
synthase 2
218247_s_a MEX3C mex-3 homolog C (C. 1.3496 0.0001
elegans)
207654_x_a DR1 down-regulator of 1.348295 9.30E-06
transcription 1, TBP-
binding (negative
cofactor 2)
209357_at CITED2 Cbp/p300-interacting 1.347165 0.0002
transactivator, with
Glu/Asp-rich carboxy-
terminal domain, 2
202241_at TRIB1 tribbles homolog 1 1.340674 0.0009
(Drosophila)
209372_x_a TUBB2A /// tubulin, beta 2A /1/
1.339095 0.0001
TUBB2B tubulin, beta 2B
205541_s_a GSPT2 G1 to S phase 1.33517 0.005
transition 2
1568815_a DDX50 DEAD (Asp-Glu-Ala- 1.329483 0.0043
_at Asp) box polypeptide
204805_s_a H1FX H1 histone family, 1.324347 0.0013
member X
213152_s_a SFRS2B splicing factor, 1.322967 6.70E-06
-44-
CA 02897444 2015-07-07
WO 2014/110053
PCT/US2014/010553
arginine/serine-rich 2B
225699_at C7or140 chromosome 7 open 1.321373 0.0014
reading frame 40
218295_s_a NUP50 nucleoporin 50kDa 1.318229 0.0014
224739_at PIM3 pim-3 oncogene 1.31654 0.0001
214911_s_a BRD2 bromodomain 1.313049 0.0015
containing 2
208938_at PRCC papillary renal cell 1.304724 0.000041
carcinoma
(translocation-
associated)
206907_at TNFSF9 tumor necrosis factor 1.295621 0.0032
(ligand) superfamily,
member 9
202284_s_a CDKN1A cyclin-dependent 1.28534 0.0001
kinase inhibitor 1A
(p21, Cip1)
206915_at NKX2-2 NK2 homeobox 2 1.280773 0.000021
215087_at C15orf39 chromosome 15 open 1.277596 0.0013
reading frame 39
202219_at SLC6A8 solute carrier family 6 1.273131 0.0006
(neurotransmitter
transporter, creatine),
member 8
202704_at 10B1 transducer of ERBB2, 1 1.272848 0.0016
213038_at RNF19B ring finger protein 19B 1.27284 0.0022
213150_at HOXA10 homeobox A10 1.272477 0.008
204383_at DGCR14 DiGeorge syndrome 1.268562 0.000043
critical region gene 14
1553613_s_ FOXC1 forkhead box Cl 1.26852 0.0003
at
218398_at MRPS30 mitochondrial 1.266043 0.0057
ribosomal protein S30
202166_s_a PPP1R2 protein phosphatase 1, 1.264115 0.00003
regulatory (inhibitor)
subunit 2
-45-
CA 02897444 2015-07-07
WO 2014/110053 PCT/US2014/010553
235004_at RBM24 RNA binding motif 1.260011 0.0086
protein 24
223742_at MRPL4 mitochondria] 1.251284 0.000049
ribosomal protein L4
211756_at PTHLH parathyroid hormone- 1.24883 0.0016
like hormone
209211_at KLF5 Kruppel-like factor 5 1.241821 0.0003
(intestinal)
225796_at PXK PX domain containing 1.239504 0.0002
serine/threonine
kinase
225434_at DEDD2 death effector domain 1.23754 0.000044
containing 2
=
208686_s_a BRD2 bromodomain 1.229145 0.0001
containing 2
217821_s_a WBP11 WW domain binding 1.218077 0.0002
protein 11
244519_at ASXL1 additional sex combs 1.208056 0.000044
like 1 (Drosophila)
208415_x_a I NG 1 inhibitor of growth 1.184054 0.0017
family, member 1
216511_s_a TCF7L2 transcription factor 7- 1.174677 0.0024
like 2 (T-cell specific,
HMG-box)
235959_at 1.172362 0.0008
243707_at 1.171741 0.0005
227852_at RP9 retinitis pigmentosa 9 1.171328 0.0002
(autosomal dominant)
1555772_a CDC25A cell division cycle 25 1.170244 0.0051
_at homolog A (S. pombe)
221841_s_a KLF4 Kruppel-like factor 4 1.16333 0.0006
(gut)
214789_x_a SFRS2B splicing factor, 1.162135 0.0001
arginine/serine-rich 2B
216997_x_a TLE4 transducin-like 1.159916 0.0001
enhancer of split 4
(E(sp1) homolog,
-46-
CA 02897444 2015-07-07
WO 2014/110053
PCT/US2014/010553
Drosophila)
205780_at BIK BCL2-interacting killer 1.158085 0.0001
(apoptosis-inducing)
212075_s_a CSNK2A1 casein kinase 2, alpha 1 1.156022 0.0049
t polypeptide
228820_at XPNPEP3 X-prolyl 1.152448 0.0008
aminopeptidase
(aminopeptidase P) 3,
putative
209653_at KPNA4 karyopherin alpha 4 1.146903 0.0004
(importin alpha 3)
209457_at DUSP5 dual specificity 1.144663 0.0016
phosphatase 5
224671_at MRPL10 mitochondrial 1.144585 0.0061
ribosomal protein L10
200618_at LASP1 LIM and SH3 protein 1 1.140405 0.0097
228931_at COQ4 coenzyme 04 homolog 1.136018 0.0008
(S. cerevisiae)
224583_at COTL1 coactosin-like 1 1.128103 0.001
(Dictyostelium)
238738_at PSMD7 Proteasome (prosome, 1.128031 0.0062
macropain) 26S
subunit, non-ATPase, 7
202501_at MAPRE2 microtubule-associated 1.12791 0.0046
protein, RP/EB family,
member 2
214321_at NOV nephroblastoma 1.123481 0.0004
overexpressed gene
202936_s_a SOX9 SRY (sex determining 1.12181 0.0054
t region Y)-box 9
222163_s_a SPATA5L1 spermatogenesis 1.116794 0.0013
t associated 5-like 1
241612_at FOXD3 forkhead box D3 1.11263 0.0041
202431_s_a MYC v-myc 1.105333 0.0007
t myelocytomatosis viral
oncogene homolog
(avian)
-47-
CA 02897444 2015-07-07
WO 2014/110053
PCT/US2014/010553
215933_s_a HHEX hematopoietically 1.105321 0.0002
expressed homeobox
204132_s_a FOX03 /// forkhead box 03 /1/ 1.100606
0.0007
FOX038 forkhead box 03B
pseudogene
201041_s_a DUSP1 dual specificity 1.09043 0.0004
phosphatase 1
230233_at 1.087609 0.0005
215223_s_a SOD2 superoxide dismutase 1.087493 0.0001
2, mitochondrial
225689_at C3orf39 chromosome 3 open 1.080337 0.003
reading frame 39
223132_s_a TRIM8 tripartite motif- 1.073976 0.0065
containing 8
203313_s_a TGIF1 TGFB-induced factor 1.073363 0.0008
homeobox 1
201461_s_a MAPKAPK2 mitogen-activated 1.070375 0.0088
protein kinase-
activated protein
kinase 2
236174_at 1.069052 0.0013
223679_at CTNNB1 catenin (cadherin- 1.060314 0.0044
associated protein),
beta 1, 88kDa
204039_at CEBPA CCAAT/enhancer 1.052213 0.01
binding protein
(C/EBP), alpha
234302_s_a ALKBH5 alkB, alkylation repair 1.049599 0.0043
homolog 5 (E. coli)
223290_at PDXP pyridoxal (pyridoxine, 1.048187 0.0022
vitamin B6)
phosphatase
226644_at MIB2 mindbomb homolog 2 1.041356 0.0011
(Drosophila)
206363_at MAF v-maf 1.037386 0.0008
musculoaponeurotic
fibrosarcoma oncogene
-48-
CA 02897444 2015-07-07
WO 2014/110053
PCT/US2014/010553
homolog (avian)
1555639_a RBM14 RNA binding motif 1.035626 0.0003
at protein 14
222527_s_a RBM22 RNA binding motif 1.027056 0.0008
protein 22
213419_at APBB2 amyloid beta (A4) 1.025879 0.0009
precursor protein-
binding, family B,
member 2
213360_s_a POM121 /// POM121 membrane 1.023715 0.0013
POM121C glycoprotein (rat) ///
POM121 membrane
glycoprotein C
225832_s_a DAGLB diacylglycerol lipase, 1.001586 0.0001
beta
212445_s_a NEDD4L neural precursor cell 0.997235 0.0022
expressed,
developmentally down-
regulated 4-like
224562_at WASF2 WAS protein family, 0.996687 0.0043
member 2
223389_s_a ZNF581 zinc finger protein 581 0.99618 0.0004
231721_at JAM3 junctional adhesion 0.989941 0.0001
molecule 3
203140_at BCL6 B-cell CLL/Iymphoma 6 0.984695 0.0004
213823_at HOXAll homeobox All 0.974615 0.0036
1552275_s_ PXK PX domain containing 0.973552 0.0002
at serine/threonine
kinase
52731_at AMBRA1 autophagy/beclin-1 0.970744 0.000027
regulator 1
238624_at 0.970064 0.0005
210479_s_a RORA RAR-related orphan 0.965295 0.0006
receptor A
220941_s_a C2lorf91 chromosome 21 open 0.943651 0.0013
reading frame 91
-49-
CA 02897444 2015-07-07
WO 2014/110053 PCT/US2014/010553
203234_at UPP1 uridine phosphorylase 0.932337 0.0009
1
202102_s_a BRD4 bromodomain 0.930432 0.0034
containing 4
217775_s_a RDH11 retinol dehydrogenase 0.92863 0.0029
11 (all-trans/9-cis/11-
cis)
Table 2. Cluster A gene list: Genes up-regulated by HSV and down-
regulated by HSV+ATA
Probe_Set_ Gene Symbol Gene_Title Estimate of p-Value
for
ID HSV1_ATA_vs_HS Estimate of
V1 HSV1_ATA_vs_HS
V1
243160_at -1.01645 0.0022
205247_at NOTCH4 Notch homolog 4 -0.93759 0.0007
(Drosophila)
219256_s_a SH3TC1 SH3 domain and -0.91997 0.0021
tetratricopeptide repeats 1
221631_at CACNA1I calcium channel, voltage- -
0.90394 0.0018
dependent, T type, alpha 11
subunit
1569961_at -0.89195 0.0013
220277_at CXXC4 CXXC finger 4 -0.85343 0.0054
229611_at LMLN leishmanolysin-like -0.85329 0.0005
(metallopeptidase M8
family)
232341_x_a HABP4 hyaluronan binding protein -0.84077 0.0071
4
242219_at -0.83521 0.0028
233767_at HHLA1 HERV-H LTR-associating 1 -0.8339 0.0017
236925_at L00728288 hypothetical L00728288 -0.81812 0.008
231905_at C20orf96 chromosome 20 open -0.80575
0.0041
-50-
CA 02897444 2015-07-07
WO 2014/110053 PCT/US2014/010553
reading frame 96
233313_at --- --- -0.80466 0.0011
1563507_at --- --- -0.79441 0.0043
232456_at C10orf71 chromosome 10 open -0.78722 0.0067
reading frame 71
203468_at CDK10 cyclin-dependent kinase 10 -0.77888 0.0035
237456_at --- --- -0.77558 0.0085
216127_at PDIA2 protein disulfide isomerase -0.76924 0.0049
family A, member 2
207977_s_a DPI dermatopontin -0.76077 0.0065
t
224510_s_a CLPB CIpB caseinolytic peptidase -0.75625 0.006
t B homolog (E. coil)
208267_at TRPV5 transient receptor -0.73228 0.0091
potential cation channel,
subfamily V, member 5
221868_at PAIP28 poly(A) binding protein -0.7284 1.10E-06
interacting protein 2B
1559439_s_ C21orf58 chromosome 21 open -0.7256 0.0051
at reading frame 58
1552960_at LRRC15 leucine rich repeat -0.72214 0.0049
containing 15
204413_at TRAF2 TN F receptor-associated -0.69678
0.0039
factor 2
213888_s_a TRAF3IP3 TRAF3 interacting protein 3 -0.69063 0.0043
t
1553945_at GPHB5 glycoprotein hormone beta -0.67838 0.0003
221312_at GLP2R glucagon-like peptide 2 -0.67682 0.0097
receptor
1554783_s_ ARHGEF2 Rho/Rac guanine -0.67352 0.0005
at nucleotide exchange factor
(GEF) 2
205567_at CHST1 carbohydrate (keratan -0.67335 0.0009
sulfate Gal-6)
sulfotransferase 1
232473_at PRPF18 PRP18 pre-mRNA -0.66869 0.0064
-51-
CA 02897444 2015-07-07
WO 2014/110053 PCT/US2014/010553
processing factor 18
homolog (S. cerevisiae)
1565583_at L0C10029133 hypothetical protein -0.66137 0.0086
6 L0C100291336
243638_at -0.65654 0.0041
208608_s_a SNTB1 syntrophin, beta 1 -0.65372 0.005
(dystrophin-associated
protein Al, 59kDa, basic
component 1)
1556202_at SRGAP2 SLIT-ROBO Rho GTPase -0.64525 0.0034
activating protein 2
206266_at G PLD1 glycosylphosphatidylinosito -0.64321 0.0015
I specific phospholipase D1
234659_at -0.63414 0.007
204708_at MAPK4 mitogen-activated protein -0.633 0.0045
kinase 4
236604_at BAHCC1 BAH domain and coiled-coil -0.63262 0.0083
containing 1
242129_at SIN3B SIN3 homolog B, -0.63025 0.0018
transcription regulator
(yeast)
233029_at OBSCN obscurin, cytoskeletal -0.62959
0.0049
calmodulin and titin-
interacting RhoGEF
203398_s_a GALNT3 UDP-N-acetyl-alpha-D- -0.62709 0.0016
galactosamine:polypeptide
N-
acetylgalactosaminyltransf
erase 3 (Gal NAc-T3)
242701_at TBRG1 transforming growth factor -0.62074 0.0032
beta regulator 1
235083_at LOC151009 hypothetical L0C151009 -0.61926 0.004
206372_at MYF6 myogenic factor 6 -0.6146 0.0018
(herculin)
1567611_at -0.61369 0.0061
236252_at -0.61329 0.0041
206286_s_a TDGF1 /// teratocarcinoma-derived -0.61123 0.0012
-52-
CA 02897444 2015-07-07
WO 2014/110053 PCT/US2014/010553
t TDGF3 growth factor 1 /1/
teratocarcinoma-derived
growth factor 3,
pseudogene
1563263_at PLCG2 Phospholipase C, gamma 2 -0.60753 0.0003
(phosphatidylinositol-
specific)
214742_at AZI1 5-azacytidine induced 1 -0.60464 0.0089
244656 at RASL1OB RAS-like, family 10, -0.6032 0.0072
member B
1555665_at --- --- -0.59953 0.0088
224291_at CACNG6 calcium channel, voltage- -0.59548 0.0068
dependent, gamma subunit
6
235616_at TSHZ2 teashirt zinc finger -0.59219 0.0037
homeobox 2
237461_at NLRP7 NLR family, pyrin domain -0.58969 0.0068
containing 7
223693_s_a RADIL Ras association and DIL -0.58969 0.0052
t domains
208454_s_a PGCP plasma glutamate -0.58916 0.001
t carboxypeptidase
216426_at TCEB1 transcription elongation -0.58852 0.002
factor B (Sill), polypeptide
1 (15kDa, elongin C)
-53-
CA 02897444 2015-07-07
WO 2014/110053
PCT/US2014/010553
Table 3A. nNOS, iNOS and eNOS expression reduction in HSV+ATA
Samples analyzed by Affymetrix Gen Array; NOS1=nNOS, NOS2=iNOS,
N053=eNOS
p-Val
Probe_Set_ID Pub_ID Symbol ATA HSV HSV+ATA p-Val ATA p-Val HSV HSV+ATA
240911_at A1733341 NOS1 1.02 1.71 1.5 0.872 0.009
0.024
207310_s_at U31466 NOS1 1 2.79 1.67 0.981 0.003
0.033
AF049656 --- N052 -1.03 2.05 1.72 0.706 0.002 0.007
205581 s at NM 000603 NOS3 1.24 2.45
_ _ _ 1.94 0.234 0.005 0.013
Table 3B. iNOS expression reduction in HSV+ATA Samples
analyzed by SABiosciences (QIAGEN) Jak-Stat RT¨PCR Microarray
p-Val
RT2 Catalog Pub_ID Symbol ATA HSV HSV+ATA p-Val ATA p-Val HSV HSV+ATA
240911_at A1733341 NOS1 1.02 1.71 1.5 0.872 0.009
0.024
-54-
